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ABSTRACT 
 MicroRNAs (miRNAs) represent a major system of post-transcriptional 
regulation, by either preventing translational initiation or by targeting messenger 
RNA transcripts for storage or degradation. miRNA deregulation has been 
reported in neurodegenerative disorders, such as Huntington’s disease (HD) and 
Parkinson’s disease (PD), which may impact gene expression and modify 
disease progression and/or severity. To assess the relationship of miRNA levels 
to HD, small RNA sequence analysis was performed for 26 HD and 36 non-
disease control samples derived from human prefrontal cortex. 75 miRNAs were 
differentially expressed in HD brain as compared to controls at genome-wide 
significance (FDR q<0.05). Among HD brains, nine miRNAs were significantly 
associated with the extent of neuropathological involvement in the striatum and 
three of these significantly related to a continuous measure of striatal 
involvement, after statistical adjustment for the contribution of HD gene length. 
Five miRNAs were identified as having a significant, inverse relationship to age 
of motor onset, in particular, miR-10b-5p, the mostly strongly over-expressed 
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miRNA in HD cases. Although prefrontal cortex was the source of tissue profiled 
in these studies, the relationship of miR-10b-5p levels to striatal involvement in 
the disease was independent of cortical involvement. In blood plasma from 26 
HD, 4 asymptomatic HD gene carriers and 8 controls, miR-10b-5p levels were 
significantly elevated in HD as compared to non-diseased and preclinical HD 
subjects, demonstrating that miRNA alterations associated with diseased brain 
may be detected peripherally. Using small RNA sequence analysis for 29 PD 
brains, 125 miRNAs were identified as differentially expressed at genome-wide 
significance (FDR q<0.05) in PD versus controls. A set of 29 miRNAs accurately 
classified PD from non-diseased brain (93.9% specificity, 96.6% sensitivity, 4.8% 
absolute error). In contrast to HD, among PD cases, miR-10b-5p was 
significantly decreased and had a significant, positive association to onset age 
independent of age at death. These studies provide a detailed miRNA profile for 
HD and PD brain, identify miRNAs associated with disease pathology and 
suggest miRNA changes observed in brain can be detected in blood. Together, 
these findings support the potential of miRNA biomarkers for the diagnosis and 
assessment of progression for neurodegenerative diseases. 
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Chapter 1: INTRODUCTION 
Background 
 Huntington’s disease (HD) is a neurodegenerative disease caused by a 
cytosine-adenine-guanine (CAG) repeat expansion in the HTT gene located on 
chromosome 4p16.3 [1]. HD is a chronic, progressive, and fatal disease, with 
motor, cognitive and psychiatric symptoms. Most individuals diagnosed with HD 
first present symptoms at middle age, beginning with the emergence of insidious 
movement abnormalities, which progresses into abrupt, nonrandom, involuntary 
choreiform movements. Chorea is a key symptom of HD and defines disease 
diagnosis. Psychological problems, such as depression or psychosis are 
commonly observed [2]. Cognitive decline and loss of executive function in 
advanced stage HD is inevitable. Survival from onset to death averages 17 to 20 
years. 
The disease is autosomal dominant transmitted, affecting an estimated 
four to eight people per 100,000 in Western countries [3]. The normal range of 
the CAG repeat region of HD gene is 8 to 26 repeats, where 40 or more repeats 
is pathogenic [4, 5]. Individuals with an intermediate repeat range between 27 
and 35 [6], and range of reduced repeats between 36 and 39, may also develop 
symptoms [7]. The CAG repeat size is inversely related to age of onset, where 
individuals with longer CAG repeat sizes are predicted to have earlier onset than 
individuals with short CAG repeat sizes [8] (see Figure 1.1). Although all HD is 
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caused by the same mutation, variability among individuals with HD is widely 
seen, with different degrees of motor and cognitive symptoms. 
Neuropathology 
The key neuropathologic feature of HD is selective neuronal loss of 
medium spiny neurons (MSNs) in the caudate nucleus and putamen, 
substructures of the striatum. Striatal atrophy begins at the tail of the caudate, 
which progresses in a rostral to caudal direction. Neuronal loss in the head of the 
caudate, near the lateral ventricle, and in the putamen, at the region closest to 
the internal capsule, occurs medially [9, 10]. Several imaging-based studies have 
identified a strong relationship between clinical features and the extent of brain 
atrophy in HD [11], indicating the loss of the inhibitory GABAergic MSNs in the 
striatum is associated with the motor aspects of the disease. Volumetric 
measurements of the caudate and putamen by MRI suggest that atrophy in the 
striatum begins 9 to 20 years prior to diagnosis [12]. 
By clustering neuropathological evaluations of 41 brain regions (rated 0-4, 
“0” being absent of change, “4” representing the highest degree of change), 
quantitative scores were created to represent the combined involvement of the 
disease within the striatal and cortical brain regions [13]. Termed the “Hadzi-
Vonsattel” score, 523 brains from the Myers lab were scored by a 
neuropathologist and assessed for their relationship to disease features. Hadzi-
Vonsattel striatal score was found to be strongly related to the size of the CAG 
expansion, where larger repeats are associated with more severe involvement at 
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time of death [10]. Cortical atrophy, however, did not relate to the extent of 
striatal involvement nor to CAG repeat size [10]. Variability in the relative to the 
involvement of cortical and subcortical regions likely influences the wide range of 
motor versus cognitive and psychiatric symptoms recognized among HD 
patients. While both cortical and subcortical regions are involved in HD [9, 14, 
15], the cortex is considerably less involved than the striatum. The mechanisms 
that lead to patient-to-patient variability in cortical and CAG-independent striatal 
neurodegeneration remain unknown. 
Molecular pathogenesis of HD 
The HD mutation produces a neurotoxic, mutant HTT protein (mHTT). The 
polyglutamine tract expansion caused by the HD mutation exists within the N-
terminal region of the HTT protein [4], which leads to aggregate formation in the 
brains of HD patients [16] as well as in HD in vitro models [17].  
Cytosolic and intranuclear inclusions containing mHTT fragments in 
neurons of the striatum and cerebral cortex are a histopathological hallmark of 
HD [18]. In post-mortem HD brains, extensive aggregation is observed in the 
striatum and in sub-layers of the cerebral cortex, and to a lesser extent, in the 
basal ganglia, hippocampus, and cerebellum [18]. Striatal MSNs and cortical 
pyramidal interneurons exhibit extensive aggregation, where aggregates initially 
localize to the soma and dendritic processes and later as the disease 
progresses, intranuclear formation occurs [18]. 
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Aberrant nuclear localization of mHTT fragments precedes cell death in 
neurons [19]. However, the process by which preferential death of striatal MSNs 
occurs is not fully understood. HD pathogenesis is likely caused by a gain-of-
function of mHTT, where the polyglutamine repeat expansion contributes to the 
misfolding and aggregate form of HTT, resulting in a protein with new, toxic 
function [20] or by the loss of wildtype HTT function through a loss-of-function or 
dominant-negative effect.  
Gain-of-function is the most well accepted hypothesis for HD 
pathogenesis. Transcription factors, such as CREB-binding protein (CBP) [21], 
specificity protein 1 (SP1) [22], TATA-binding protein (TBP) [23] and p53 [21], 
and transcriptional repressors such as REST/NSRF [24], spuriously bind to 
mHTT intranuclear inclusions impairing their normal activity, leading to 
transcriptional dysregulation [25]. The transcription factor nuclear factor kappa-
light-chain-enhancer of activated B cells (NFkB), which is particularly related to 
immune function, has shown altered activity in HD due to direct, aberrant 
interactions with soluble mHTT [26, 27]. 
The HD gene encodes a large, 348 kDa cytosolic protein (HTT) that is 
widely distributed throughout the body, with its highest levels in the brain [28, 29]. 
The protein structure of HTT suggests it is a multifunctional scaffolding protein, 
with multiple HEAT repeats and hydrophobic alpha-helices that assist in protein-
protein interactions, and a nuclear export signal [30] which aids in nuclear 
transport. HTT directly associates with the microtubule motor dynenin [31], and 
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indirectly binds kinesin-1 through Huntingtin-associated protein 1 [32], 
modulating the bidirectional transport of endocytic and exocytic vesicles along 
cytoskeletal tracks [33]. Within RNA transport granules, HTT colocalizes with 
Argonaute 2, a component of the RNA-induced silencing complex, indicating it 
may play a role in localized translational control through the silencing of RNA 
transcription [34, 35]. HTT is critical for nervous system development [36] and 
embryonic lethal in knockout huntingtin mice [37]. HTT may also play a role in 
cytokine production in monocytes and macrophages under normal and HD 
settings [38]. 
HD is associated with the disruption of an assortment of cellular 
processes, impairing cell adhesion[39], mitochondrial energetics [40], cellular 
transport [41], autophagic processing  [42], ubiquitin–proteasome system [43], 
synaptic plasticity [44] and enhancement of glutamate-related excitotoxicity [45]. 
HTT cleavage is mediated by caspases to produce an amino-terminal polyQ 
containing fragment [46], and mHTT is more susceptible to cleavage than its 
normal counterpart. The N-terminal region is cleaved by caspases and calpains 
to produce N-terminal fragments in both normal and HD cells, where only the 
expanded polyQ fragments of HD self-associate and seed aggregates [47-49]. 
Activation of caspases induces apoptosis; thus, overactive caspases have 
deleterious effects on already stressed neurons.  
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Parkinson’s disease 
Background 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disease, characterized by resting tremor, rigidity, bradykinesia and postural 
instability [50]. The loss of dopamine-producing neurons in the substantia nigra 
par compacta, a substructure of the basal ganglia, is a hallmark of PD 
neuropathology. Reduction of dopaminergic neurons results in dopamine 
depletion, improper regulation of the nigrostriatal pathways, consequently 
hypokinesia. 
Neuronal cytoplasmic inclusions, termed Lewy bodies, and Lewy neurites 
found in neuronal processes, are observed throughout the brain [51]. Lewy 
bodies predominantly consist of α-synuclein protein, and to a lesser extent, 
ubiquitin, calbindin, and tubulin [51]. α-synuclein is a small, 140 amino-acid 
protein found in high abundance at the presynaptic terminal of neurons, 
representing up to 1% of all cytosolic protein found in the brain [52]. A predictable 
topography of pathological changes in the central nervous system is observed, 
as annotated by Braak [53], beginning in olfactory bulb and medulla oblongata, 
then progressing rostrally from the medulla to the pons, then to the substantia 
nigra and midbrain, limbic structures, and neocortical structures.  
α-synuclein has the ability to generate β-sheet structures under specific 
physiological conditions, creating amyloid-like fibrils. Soluble, oligomeric α-
synuclein can transition into spherical, string-like, protofibrils, which gradually 
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assemble into insoluble, neurotoxic fibrils [51]. Injection of protofibrils into PD 
mouse models results in widespread aggregate deposition in the brain [54], 
which indicates transmission of the protofibrils through neural connectivity. 
The mechanism by which dopaminergic neurons preferentially degenerate 
likely occurs through several converging pathways. α-synuclein accumulation is 
neurotoxic. Oligomeric α-synuclein may lead to dopamine leakage of 
neurotransmitter filled vesicles into the cytosol, which could lead to oxidative 
stress-induced death [55]. Cytosolic dopamine contributes to oxidative stress and 
cellular damage, by disrupting glutathione homeostasis, enhancing calcium 
influx, increasing calcium-mediated calpain activation and supporting in free 
radical production [56]. Neurotoxins, such as 6-hydroxydopamine (6-OHDA), 
MPTP, and the pesticide paraquat, have been shown to destroy DA neurons, and 
individuals that have exposure to these chemicals display Parkinsonism [57]. 
These toxins infer with complex I of the electron transport chain, causing the 
increase of free radicals and halting mitochondrial metabolism, leading to cell 
death [58]. In PD, impaired energetics by mitochondrial dysfunction may be 
aggravated by abnormal proteostasis, as normal clearance of proteins by 
chaperone-mediate autophagy or other proteolytic mechanisms may be impaired 
[59]. Both neuronal and glial sources have been implicated in the contribution of 
oxidative stress, and chronic neuroinflammatory activity from dying cells or 
inclusion bodies may play a role in the degenerative process [60]. 
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Genetic heterogeneity 
The underlining mechanism of α-synuclein misfolding and insoluble 
aggregation is poorly understood. However, the discovery of genetic forms of PD 
caused by mutations of the α-synuclein gene (SNCA) [61-67], have led to its 
identification and insight into PD pathogenic mechanisms. Multiplication of SNCA 
(duplication and triplication of the gene) leads a dominant forms of PD, and 
SNCA levels of gene expression inversely related to age of onset of PD [68]. A 
missense substitution (A53T) impacts protein clearance and also leads to 
dominant inheritance. 
Mendelian and complex forms of PD [61] may provide novel insight into 
disease etiology and pathological mechanisms. Mutations of the leucine-rich 
repeat kinase 2 gene (LRRK2) represent the most common inherited form of PD 
[68]. 13 other Mendelian forms have been identified, and this number will 
continue to grow as genome-wide methods are continually applied [68]. Many of 
these genes, including parkin, DJ-1, and PINK, are linked to respiration and 
mitochondrial function.  
Due to the occurrence of reduced penetrance, variable expressivity, and 
environmental phenocopy effects, pedigrees often lack Mendelian patterns of 
inheritance. Genome-wide association studies illustrate the complex etiology of 
PD and genetic heterogeneity of the disease. The results from the mega-meta 
PD GWAS over (~13,000 PD, 80,000 control), identified 24 loci, and the second 
most significant locus, microtubule-associated protein tau (MAPT), also encodes 
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for the protein which when phosphorylated, is present in aggregates in 
tauopathies and Alzheimer’s disease [61]. However, GWAS variants only 
account for an estimated 30% of familial and 5% of sporadic, non-familial cases 
[69, 70].   
Preclinical and progressive biomarkers for neurodegenerative disease 
Huntington’s disease biomarkers 
Although genetic testing allows for reliable detection of HD (by sequencing 
of the CAG repeat of the HD gene), there remains a need for biomarkers of 
disease progression in premanifest individuals. The mechanism by which 
premanifest HD gene carriers transition to manifest HD remains unknown. 
Slowing disease progression may delay the onset of disease symptoms.  
Clinical progression of HD can be measured by a number of clinical tests. 
The Unified Huntington Disease Rating Scale (UHDRS) is the gold standard, 
which assesses of the degree of motor, cognitive, and behavioral involvement as 
well as total functional capacity (TFC) and degree of independence [2].  Although 
UHDRS may be able to determine the extent of deterioration of executive 
functioning (as measured by TFC), its utility is limited to symptomatic, early and 
mid-stage HD patients. 
As HD progresses, the brain loses significant volume, and these early 
structural changes are observable using magnetic resonance imaging (MRI) in 
premanifest individuals. A 50% reduction in volume of the putamen and 28% 
reduction of the caudate nucleus has been observed in early stage HD patients 
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[71]. TRACK-HD, a large (n=366) cross-sectional study aimed to discover 
baseline predictors of HD progression, observed volumetric changes in 
premanifest HD across a 36 month period, and in early symptomatic HD patients, 
these changes correlated with progression [72]. Results from PREDICT-HD, 
another large HD cohort, estimated that volumetric brain changes might be 
detectable up to 15–20 years prior to diagnosis [73]. The severity of HD clinical 
manifestations relate to the loss of neurons, but also to neuronal dysfunction and 
synaptic changes as measured by functional MRI (fMRI). Increased activation of 
the dorsolateral prefrontal cortex was observed in presymptomatic individuals as 
they approached disease onset, independent of cortical atrophy [74]. Increased 
neuroinflammation, measured by microglial activation [75, 76] or proinflammatory 
cytokines (such as TNF-α, IL-6, IL-8) in blood has been observed in premanifest 
and early stage HD [77].  
Altered dopamine signaling may play a role in HD pathogenesis. Positron 
emission tomography (PET) based imaging using radiolabeled striatal dopamine 
receptors (D1, D2) and well as dopamine transporter (DAT), have shown 
decreased postsynaptic receptor density and binding in asymptomatic HD gene 
carriers and HD patients [78]. Brain metabolism can also be measured using 
PET. Reduced glucose uptake was first observed in mice with neostriatal lesions, 
using 14C-2-deoxyglucose (DG) autoradiography [79] and later, glucose 
hypometabolism in human neostriatum was shown to preceded degeneration 
and correlate with motor impairments [80-83].  
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Increased levels of leukocyte 8-hydroxydeoxyguanosine (8-OHdG), a 
marker of free radical oxidative damage to DNA, have been observed in the 
caudate and parietal cortex [84], serum [85], and leukocytes [86]. Increased 8-
OHdG levels were observed in premanifest individual in longitudinal studies, with 
higher levels in those with larger repeats or older ages [87]. However, these 
results were not repeatable in an independent cohort, assayed by two separate 
using two assay protocols (LCECA, LC-MSMS) [88]. Phosphodiesterase 10A 
(PDE10A) using [18F]MNI-659, PET imaging tracer selective for the striatum, has 
shown promise in preliminary cross-sectional and longitudinal studies, where 
reduced PDE10A levels correlate with clinical measures of disease severity [89].  
Although precise and accurate anatomical or functional endpoints can be 
measured using neuroimaging, poor reproducibility can result due to the lack of 
standardization. Imaging is susceptible to unreliability across centers, due to 
differences in data acquisition, the handling of motion artifacts, scanner models, 
image processing, the software for normalization, the reference for spatial 
mapping and overall analysis [90]. 
Ideally, assays that predict the continuum of HD would be derived from 
peripheral biofluids, due to cost effectiveness, simplicity and ease of clinical 
adoption. As immunoassays improve, mHTT may be a tractable biomarker for 
HD progression. The extent of accumulation of mHTT protein in peripheral fluids 
such as sorted blood cells [91] and cerebrospinal fluid [92], can be measured 
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using high-resolution immunoassays. In cerebrospinal fluid, using single 
molecular counting for mHTT, mHTT was detectable only in HD gene carriers, 
was three times higher in symptomatic HD as compared to premanifest HD gene 
carriers, and was associated with of cognitive and motor dysfunction in 
symptomatic HD patients [92]. However, these results, while encouraging, are 
relatively new and yet to be reproduced. 
Several studies describe the early and chronic elevation of 
proinflammatory cytokines in HD blood cells but these signals do not provide the 
resolution needed to track disease progression [31-33]. Researchers have 
attempted to use a candidate gene approach, in particular in probing 
inflammatory cytokine genes, with little success [34,35].  
Genome-wide genomic profiling is an attractive option for HD diagnostics, 
as these tests have the ability to measure cellular state with high-resolution. A 
set candidate genes identified in genome-wide studies can be easily 
standardized with PCR-based tests or as DNA sequencing technologies continue 
to improve, a set of genes could efficiently tested with a single assay. H2A 
histone family, member Y (H2AFY) mRNA was found to overexpressed in HD 
prefrontal cortex and HD patients compared to controls, and was recent validated 
by an independent study [93], which used RNA-sequencing of peripheral blood 
cells to identify 167 genes that related to clinical motor scores [93]. Although 
these results lacked concordance to a previous blood study [94], the 
concordance of H2AFY mRNA is encouraging. Discrepancies could be due to the 
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technologies used (microarray versus sequencing), the susceptibility of RNA to 
nucleases and the relatively short half-life of messenger RNA, estimated from 15 
minutes to 17 hours in vitro [36]. Other representative genomic markers, such as 
miRNAs, with high stability and long half-lives [38-40] may be more useful for HD 
prediction.  
Parkinson’s disease biomarkers 
PD diagnostics apply similar strategies as in HD, however isolating 
preclinical PD patients is difficult. Additionally, the diagnosis of idiopathic PD is 
encumbered by the heterogeneous presentation of symptoms, distinctive clinical 
subtypes (PD, PDD), and variable rates of progression.  30% of PD patients have 
PD-related dementia [95]. Monogenic, familial forms only represent a small 
sample of PD patients.  
Three phases have been proposed – preclinical, premotor, and motor 
phases of PD [96]. In the preclinical phase, no symptoms are present. Nonmotor 
manifestations are detectable in the premotor phase. Prodromal or premotor 
markers include olfactory dysfunction [97], neuropsychiatric, and autosomal 
changes such as gastrointestinal complications [98], or sleep abnormalities 
(excessive sleepiness [99],  idiopathic REM sleep behavior disorder [100]).  Over 
90% of patients with PD have olfactory dysfunction [97], and using the Brief 
Smell Identification Test in 2,267 healthy males, longitudinal tests found the odds 
of PD development within 4 years in the lowest quartile of olfactory acuity to be 
5.2 times that observed in the highest two quartiles [101].  Clinical measures of 
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PD progression of motor symptoms and cognitive decline can be assessed by 
the Unified Parkinson's Disease Rating Scale (UPDRS), a battery of tests 
comprised of six tests, measuring cognitive health, complications of therapy, 
extent of motor involvement, level of independence as severity of PD symptoms 
as measured by the Hoehn and Yahr scale [102].These measures are used for 
diagnosis, clinical evaluation and monitoring of the rate of functional decline in 
PD. 
The onset of DA loss precedes motor symptoms. Image based analysis 
using radioligands for DA transporter to assess the integrity of the dopaminergic 
system have been successful in some instances of differentiating the degree of 
PD severity [103]. In a longitudinal 3-center observational study with 37 months 
of prospective follow-up, a 17-fold increased for the relative risk for developing 
PD was observed among those with transcranial sonography substantia nigra 
hyperechogenicity [104], occurring in over 90% of PD patients, compared to 10% 
of healthy older adults. Histopathological evidence from gastrointestinal tract 
neurons, from colonic submucosa of PD patients, was positive for α-synuclein 
accumulation [105]. Biochemical screening methods for Lewy body related 
proteins in peripheral fluids like CSF and blood might act as high-resolution 
biomarkers. In postmortem CSF from PD and control subjects, assaying six 
proteins (fibrinogen, transthyretin, apolipoprotein E, clusterin, apolipoprotein A-1, 
and glutathione-S-transferase-Pi), using two-dimensional difference gel 
electrophoresis, PD samples differed by 1.5-fold in protein concentration [106]. 
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Comparing protein levels in the CSF of 42 PD and 69 controls, in PD, increased 
α-synuclein levels were associated with progression of motor symptoms and 
cognitive decline over 2 years, lower levels of Aβ was associated with worsening 
of performance on delayed memory recall, and high levels of phosphorylated tau 
were associated with worsening in motor symptoms [107]. 
Genome-wide transcriptomics have been used for PD biomarker 
discovery. In an RNA-seq study of blood, asymptomatic individuals with the 
G2019S LRRK2 mutation were compared to idiopathic PD and health controls, to 
identify genes that may be specifically altered in LRRK-related PD [1]. In a study 
of 105 total patients, microarrays were used to create a detail transcriptomic 
profile of early-stage PD peripheral blood, and though differentially expressed 
genes were identified, classification of PD based on RNA expression failed in 
validation [2]. Reanalysis of these data identified a set of 10 genes that may 
predict PD using PCA [3]. Levels of seven brain-relate genes were measured in 
blood samples from 62 early-stage PD patients and 64 controls, and using a 
stepwise multivariate logistic regression analysis, five genes were identified as 
disease predictors of PD (sensitivity 90.3, specificity 89.1, ROC AUC=0.96, 
validated AUC=0.95) [4]. After induction of deep brain stimulation, RNA changes 
were observed in PD leukocytes [108, 109]. Using network analysis from four 
independent microarray studies, hepatocyte nuclear factor 4 alpha (HNF4A) and 
polypyrimidine tract binding protein 1 (PTBP1) were significantly altered in blood 
from two independent cohorts, and based on their levels, exhibited significant 
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longitudinal changes over the course of the 3 year follow-up period and classified 
PD with 90% sensitivity and 80% specificity [110]. mRNA biomarkers in blood 
may be informative for identifying PD-related genes, but due to their inherent 
lability and patient-to-patient variability, other markers, such as microRNAs, may 
be representative of mRNA changes but more biochemically stable.  
Role of miRNAs in neurodegenerative diseases 
MicroRNAs (miRNAs) are small non-coding RNAs, 18-25 nucleotides in 
length, which bind complementary sites within the 3’ untranslated regions of 
messenger RNA. Through the assembly of the RNA-induced silencing complex 
(RISC), the duplexed transcript signals for degradation by endonuclease 
cleavage, or preventing translation of the gene product by stalling protein 
synthesis machinery [111] (see Figure 1).  As translational regulators of mRNA 
expression, miRNAs can directly control cell fate decisions, and consequently, 
miRNAs are involved in numerous aspects of embryonic and neurodevelopment 
[112]. 
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Figure 1. Schematic of miRNA biogenesis. 
Primary transcripts are transcribed and processed by DROSHA, exported from 
the nucleus by Exportin 5, trimmed by DICER and loaded into RISC to become 
active silencers. Insoluble aggregates can affect normal miRNA mechanisms, by 
increasing mRNA content due to spurious protein binding or impairing miRNA 
complex activity. 
	
Dysregulation of miRNAs has been linked to neurological and 
neurodegenerative disorders [113] and several studies have explored the role of 
miRNAs in HD (see Figure 2). In targeted study, Parker et al 2008 observed 
miRNAs predicted to target RE1-silencing transcription factor (REST), a 
transcriptional repressor which has enhanced function as mHTT fails to prevent 
its nuclear translocation and subsequent downstream repressive effects of 
neuroprotective genes [114]. Marti et al [115] performed miRNA-sequencing for 
two pooled HD samples and two pooled control samples, and while a number of 
miRNA differences were observed, differential expression could not be 
performed. Altered expression of miRNAs, quantified using microarray 
technology, has been reported in cellular models of HD [114, 116, 117] and in 
mouse models of HD [117-120], which either focus on REST/CoREST-related 
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miRNAs or miRNAs which are predicted to target HTT. Most telling may be the 
interaction of HTT with important miRNA-related machinery. Wildtype HTT was 
found to colocalize with Argonaute 2, the endonuclease required for RNA-
mediated gene silencing by the RNA-induced silencing complex (RISC), within 
neuronal transport RNA granule [121, 122], suggesting HTT may facilitate 
miRNA-mediated mRNA degradation and/or localized translation of specific 
mRNAs.  
Figure 2. Proposed HD miRNA mechanisms. 
 
Kim et al. 2007 was the first to highlight the importance of miRNA function 
within the dopaminergic system [123]. Dicer, the enzyme responsible for the 
cleavage of primary miRNA into their mature, active form, was genetically 
removed exclusively in post-mitotic, dopaminergic neurons. Dicer-null neurons in 
these transgenic mice into lived into adulthood, but later in life, mice displayed 
PD-like phenotypes and dopamine-expressing neurons were progressively lost. 
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In vitro, these neurons were unable to maturate but were effectively rescued with 
the addition of small endogenous RNAs [123]. While specific miRNAs were 
altered in the midbrain of these mice, subsequent genetic studies have found no 
association of these miRNAs or their target to PD [124]. However, miRNAs have 
been observed to modulate of alpha-synuclein protein expression, and single 
nucleotide polymorphisms (SNPs) in the 3’UTR of SNCA [125], as well as SNCA 
3’UTR length, may be associated with PD, revealing a potential role of SNCA-
binding miRNAs in PD [126-128]. Several miRNAs that we reported altered in PD 
brain may have an indirect relationship to PD-related genes (see Figure 3). 
Genetic forms of PD include mutations within the α-synuclein gene (SNCA), as 
well in Leucine-rich Repeat Kinase 2 (LRRK2), one of the most common causes 
of familial PD [61]. miR-34b/c was identified as being altered in brain from 
microarray, however genome-wide changes were not reported [129]. A number 
of PD blood studies have been performed with little concordance [130-134], 
although miRNA in blood of PD patients after Levodopa treatment showed 
suggestive alterations [135]. In Burgos et al. 2014, small RNA sequencing was 
performed for blood serum and CSF from 67 PD and 78 control postmortem 
subjects [136], a number of changes were reported, but without information from 
brain, were difficult to interpret. 
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Figure 3. Proposed PD miRNA mechanisms. 
 
Commonly, miRNA biomarker studies have been initiated in blood or other 
peripheral biofluids, and their relationship to neuropathological involvement has 
not been considered.  As noted above, both HD and PD are known to have 
physiological complications such as gastrointestinal problems, weight loss, sleep 
disorders, as well as autonomic and sensory dysfunctions.  It is likely that some 
of these changes produce alterations in blood that are not indicative of the 
underlying neurodegenerative process and thus would not predict the 
neurologically dependent disease processes. By using primarily affected tissue, 
such as prefrontal cortex, from postmortem patient samples as an initial miRNA 
screening approach, candidate miRNAs can be selected for studying the 
periphery, decreasing noise and irrelevant signals such as physiological changes 
which do not explain disease progression. A comprehensive evaluation of the 
correspondence of brain miRNA and miRNA detectible in biofluids is the logical 
first in the effective detection of HD and PD biomarkers.   
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Biochemically, miRNAs are relatively stable. The half-life of the majority 
miRNA has been predicted to be on average 5 days [137]. Plasma miRNAs have 
been observed unaffected by extreme heat or pH, long-time storage at room 
temperature, or multiple freeze-thaw cycles [38-40]. The small size of miRNA 
allow higher potential for neuropathologically specific miRNA to cross the blood-
brain barrier in exosomes [138] and circulate stably in peripheral fluids as cell 
free molecules [139]. The ability of miRNA to circulate provides a unique 
opportunity to monitor the neurological disease processes from the periphery. 
miRNA sequencing offers high-resolution detection over a wide dynamic 
range of miRNA levels to create a detailed miRNA profile. miRNA sequence 
analysis would provide the most accurate and comprehensive miRNAs signature 
in HD or PD, to identify neuropathologically and potentially clinically relevant 
miRNA for biomarker discovery. 
 
Hypothesis and Specific Aims 
Hypothesis 
We hypothesize miRNAs are altered in Huntington’s and Parkinson’s 
disease brain. As key post-transcriptional regulators, miRNAs associated with 
disease may also help describe neuropathology or disease features, such as the 
age of motor onset. Due to their stability and extracellular transport, brain-related 
miRNA changes may be observed in the blood, and therefore function as 
potential disease classifiers or predictors of disease phenotypes. 
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Specific Aims 
Aim 1: Characterize miRNA expression in HD brain. We will perform 
Illumina small non-coding next-generation sequencing on 42 Brodmann Area 9 
(BA9) prefrontal cortex samples (16 HD, 26 controls), and combine this cohort 
with our initial study of 12 HD and 9 controls to identify disease-related miRNA. 
Additional samples will provide statistical power and confidence needed to find 
differentially expressed miRNA, as well as model relationships of clinical features 
of HD, such as age of disease onset, age at death, and extent of 
neurodegeneration in striatum and prefrontal cortex, to miRNA expression.  
Aim 2: Evaluate blood plasma miRNAs as circulating biomarkers for 
HD disease progression. We will assess whether brain-specific miRNA 
changes are peripherally observable. Using blood plasma-derived RNA collected 
from a cohort of 26 HD, 4 asymptomatic HD gene carriers and 8 controls, we will 
measure levels of miR-10b-5p, miR-486-5p, miR-132-3p and miR-363-3p, four 
miRNAs with associations to the extent of striatal involvement and/or onset age. 
We will compare the levels across the three groups to identify whether miRNA 
levels associate with disease stage.  
Aim 3: Characterize miRNA levels in Parkinson’s disease brain. We 
will perform sequencing in 29 PD prefrontal cortex and using our existing 
controls, compare the two groups to identify genome-wide miRNA alterations in 
PD brain. We will use classification analysis to find a miRNA profile for PD, and 
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identify miRNAs that relate to disease phenotypes, such as onset age and 
dementia.  
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CHAPTER 2: MICRORNAS LOCATED IN THE HOX GENE CLUSTERS ARE 
IMPLICATED IN HUNTINGTON’S DISEASE PATHOGENESIS 	
Citation: 
Hoss AG, Kartha VK, Dong X, Latourelle JC, Dumitriu A, Hadzi TC, et al. (2014) 
MicroRNAs Located in the Hox Gene Clusters Are Implicated in Huntington's 
Disease Pathogenesis. PLoS Genetics 10(2): e1004188. doi: 
10.1371/journal.pgen.1004188 	
Abstract 
Transcriptional dysregulation has long been recognized as central to the 
pathogenesis of Huntington’s disease (HD). MicroRNAs (miRNAs) represent a 
major system of post-transcriptional regulation, by either preventing translational 
initiation or by targeting transcripts for storage or for degradation. Using next-
generation miRNA sequencing in prefrontal cortex (Brodmann Area 9) of twelve 
HD and nine controls, we identified five miRNAs (miR-10b-5p, miR-196a-5p, 
miR-196b-5p, miR-615-3p and miR-1247-5p) up-regulated in HD at genome-wide 
significance (FDR q-value <0.05). Three of these, miR-196a-5p, miR-196b-5p 
and miR-615-3p, were expressed at near zero levels in control brains. 
Expression was verified for all five miRNAs using reverse transcription 
quantitative PCR and all but miR-1247-5p were replicated in an independent 
sample (8HD/8C). Ectopic miR-10b-5p expression in PC12 HTT-Q73 cells 
increased survival by MTT assay and cell viability staining suggesting increased 
expression may be a protective response. All of the miRNAs but miR-1247-5p 
are located in intergenic regions of Hox clusters. Total mRNA sequencing in the 
same samples identified fifteen of 55 genes within the Hox cluster gene regions 
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as differentially expressed in HD, and the Hox genes immediately adjacent to the 
four Hox cluster miRNAs as up-regulated. Pathway analysis of mRNA targets of 
these miRNAs implicated functions for neuronal differentiation, neurite outgrowth, 
cell death and survival. In regression models among the HD brains, huntingtin 
CAG repeat size, onset age and age at death were independently found to be 
inversely related to miR-10b-5p levels. CAG repeat size and onset age were 
independently inversely related to miR-196a-5p, onset age was inversely related 
to miR-196b-5p and age at death was inversely related to miR-615-3p 
expression. These results suggest these Hox-related miRNAs may be involved in 
neuroprotective response in HD. Recently, miRNAs have shown promise as 
biomarkers for human diseases and given their relationship to disease 
expression, these miRNAs are biomarker candidates in HD. 
Introduction 
 Huntington's disease (HD) (OMIM: 143100) is an inherited 
neurodegenerative disorder characterized by involuntary movement, dementia, 
and changes in personality. HD is transmitted as an autosomal dominant 
disorder, for which an expansion of a CAG trinucleotide repeat within the coding 
region of the huntingtin gene (HTT) is the disease causing mutation [1]. The CAG 
repeat codes for a polyglutamine domain in the Htt protein and results in 
neuronal cell death predominantly affecting the caudate nucleus and putamen 
although neuronal loss is widespread in the HD brain [2,3]. While the biological 
processes leading to neurodegeneration in HD are poorly understood, 
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transcriptional dysregulation has long been proposed as central to the 
pathogenesis of HD. Widespread alterations in gene expression have been 
reported [4] and several studies suggest that gene expression may be altered at 
one or more of the stages of RNA processing, translation, protein post-
translational modification or trafficking [5,6].  
 MicroRNAs (miRNAs) are small non-coding RNAs that function as 
translational regulators of mRNA expression. miRNAs may inhibit gene 
expression either by repressing translation, or by targeting mRNA for either 
storage or degradation [7]. Recently, dysregulation of miRNAs has been linked to 
neurological and neurodegenerative disorders [8] and several studies have 
explored the role of miRNAs in HD. Marti et al [9] performed miRNA-sequencing 
for two pooled HD samples and two pooled control samples and reported altered 
expression for a large number of miRNAs. Altered expression of miRNAs, 
quantified using microarray technology, has been reported in cellular models of 
HD [10-12] and in mouse models of HD [12-15] but a comprehensive study of 
miRNA and mRNA expression obtained through next-generation sequencing 
technology in human HD samples has not been performed. 
 In order to investigate (1) the presence of altered miRNA expression and 
(2) the potential role of miRNAs on the altered mRNA expression seen in HD, we 
performed both miRNA-sequencing and mRNA sequencing, using Illumina 
massively parallel sequencing in twelve HD and nine neurologically normal 
control brains. To our knowledge this is the first genome-wide quantification of 
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miRNA expression comparing human HD and control brain, and the first to 
combine total miRNA expression with total mRNA expression obtained through 
massively parallel sequencing.  
Results 
Selection of prefrontal cortex and BA9. While the striatum is the region 
most heavily involved neuropathologically in HD [3], 80% to 90% of the neurons 
in that region will have degenerated by the time of death. These changes, 
together with the presence of reactive astrocytosis, alter the cellular composition 
of the striatum. In contrast, cortical involvement in HD is well defined [2,16] and 
while it does not experience dramatic neuronal degeneration, cortical neurons 
are known to exhibit the effects of protein aggregation and nuclear inclusion 
bodies characteristic of the disease. Therefore, we selected the prefrontal cortex 
for these studies. 
Table 1. HD brain samples analyzed for mRNA-seq, miRNA-seq and RT-
qPCR validation of miR-10b-5p. 
All of the HD samples passed mRNA-seq QC. Scale of neuron loss: 0=absent, 
1=mild, 2=moderate 	
		
Sample ID miRNA-seq RT-qPCR PMI (hr.) RIN or RQN Death age Onset age
Duration 
(yr.)
CAG repeat 
size
Neuron 
Loss in 
Neocortical 
Gray Matter
HD-01 Passed Y 37 7.1 55 44 11 45 1
HD-02 Passed Y 6 7.5 69 63 6 41 1
HD-03 Passed Y 21 7 71 52 19 43 1
HD-05 Passed Y 19 6.9 48 25 23 48 2
HD-06 Passed Y NA 6.2 40 34 6 51 1
HD-07 Passed Y 8 8.5 72 55 17 41 1
HD-08 Passed Y 21 7.4 43 NA NA 49 1
HD-09 Passed Y 4 7.8 68 45 23 42 1
HD-10 Passed Y 6 8.3 59 35 24 46 1
HD-12 Passed Y 13 6 68 52 16 42 0
HD-13 Passed N 25 6.1 57 40 17 49 1
HD-14 Passed Y 11 7.3 48 38 10 45 1
Mean - - 15.48 7.18 58.17 43.91 15.64 45.17 0.875
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Table 2. Control brain samples analyzed for mRNA-seq, miRNA-seq and 
RT-qPCR validation of miR-10b-5p. 
All the control samples passed mRNA-seq QC. 
RIN = RNA Integrity Number, RQN = RNA Quality Number, PMI = Postmortem 
Interval 	
	
 
Five miRNAs are up-regulated in HD. After removing sample outliers 
using principal component analysis filtering, we identified five out of 1,417 
detected mature miRNA species as differentially expressed between twelve HD 
and nine control prefrontal cortex samples using the R statistical package DESeq 
(Tables 1, 2 and 3; Figure 4). All five miRNAs were significantly up-regulated in 
HD. The largest effect between conditions was seen for miR-10b-5p, with a 28.41 
fold increased expression in HD relative to control samples (mean control 
expression=915.81; mean HD expression=26,020.05, Figure 4). miR-1247-5p 
was expressed at moderate levels in both control (mean=49.44) and HD brain 
(mean=102.01). Three of the miRNAs, miR-196a-5p (mean control 
PMI
(hr.)
C-14 Passed Y 21 8 79
C-21 Passed Y 26 7.3 76
C-29 Passed Y 13 6.4 93
C-31 Passed Y 24 7.3 53
C-32 Passed Y 24 8.3 57
C-33 Passed Y 15 7.5 43
C-35 Failed PCA N 21 7.6 46
C-36 Passed Y 17 7.5 40
C-37 Failed PCA N 28 8.3 44
C-38 Passed Y 20 7.7 57
C-39 Passed Y 15 7.3 80
Mean - - 20.36 7.49 60.73
Sample ID miRNA-seq RT-qPCR RIN or RQN Death age
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expression=1.47; mean HD expression=27.49), miR-196b-5p (mean control 
expression=2.49; mean HD expression=11.01) and miR-615-3p (mean control 
expression=1.09, mean HD expression=6.66), had near zero expression levels in 
all nine control samples.  
Table 3. Differentially expressed miRNAs from miRNA-seq 
* FDR-adjusted q-value 	
	
 
Figure 4. miR-196a-5p, miR-10b-5p and miR-615-3p were found significantly 
differentially expressed in Huntington's disease 
miR-10b-5p, miR-1247-5p, miR-196a-5p, miR-196b-5p, and miR-615-3p were 
identified as differentially expressed in Huntington’s disease prefrontal cortex 
compared to non-neurological disease controls by Illumina miRNA-sequencing. 
Normalized expression values quantified from DESeq analysis are shown on the 
y-axis. miR-196a-5p, miR-196b-5p and miR-615-3p were essentially not 
expressed in control samples, while the mean HD expression was 27.49, 11.01 
and 6.66 respectively. miR-1247-5p was expressed at moderate levels in both 
control (mean=49.44) and HD brain (mean=102.01). miR-10b-5p was expressed 
in control (mean=915.81) and highly expressed in HD brain (mean=26,020.05). 
For miRNA, *p<0.05 and ***p<0.001, as determined by DESeq, followed by the 
Benjamini-Hochberg multiple comparison correction. (HD=Huntington’s disease). 	
miRNA Control expression
HD 
expression
Fold 
Change p-value q-value *
miR-196a-5p 1.47 27.49 18.66 2.05E-10 2.91E-07
miR-10b-5p 915.81 26020.05 28.41 1.99E-08 1.41E-05
miR-615-3p 1.09 6.66 6.09 2.73E-05 1.29E-02
miR-1247-5p 49.44 102.01 2.06 7.67E-05 2.72E-02
miR-196b-5p 2.49 11.01 4.41 9.77E-05 2.77E-02
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Validation and replication of miRNA findings. miRNA expression 
differences were orthogonally validated using the Exiqon miRCURY LNA™ 
technology for reverse transcription quantitative PCR (RT-qPCR) in eleven of 
twelve sequenced HD samples and nine control samples originally studied for 
miRNA-seq. All five miRNAs were confirmed to be significantly up-regulated in 
HD, consistent with our miRNA-sequencing findings.  
To replicate our findings in an independent sample set, we performed RT-qPCR 
in an additional eight control and eight HD prefrontal cortical samples.  Four out 
of five miRNA (miR-10b-5p, miR-196a-5p, miR-196b-5p, miR-615-3p) were 
confirmed as significantly increased in expression in HD. 
Similar proportion of neurons in HD and control cortical brain 
homogenate samples. HD is characterized by progressive cortical atrophy, with 
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recognizable neuropathologic abnormalities in the neocortical gray matter [2,16-
20] (Table 1). To address whether miRNA expression changes in HD may be 
due to altered ratios in brain cell-type abundance, such as a change in the ratio 
of neurons to glial cells, we compared the number of neuronal and non-neuronal 
nuclei across conditions. Suspensions of cell nuclei of prefrontal cortex from 28 
HD cases and 19 controls were immunocytochemically labeled with anti-NeuN, a 
neuron-specific nuclear antigen, followed by flow cytometric analysis. The mean 
and range of NeuN+ ratios for controls and cases were not significantly different 
(t=1.67, p-value=0.10; Figure 5), suggesting cortical neuron loss in the BA9 area 
in HD is relatively modest and does not account for the dramatic alterations in 
miRNA levels reported here.    
 
Figure 5. Neuron counts from prefrontal cortical tissue homogenate. 
No significant difference is observed when comparing ratios of NeuN+ counts to 
total events quantified by flow cytometry. 		
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Increased miR-10b-5p expression is not observed in Parkinson’s 
disease (PD). To establish whether miR-10b-5p change is a generalized 
response to neurodegeneration, we evaluated this miRNA in PD prefrontal 
cortex. While cortical neuronal loss is variable in PD, both PD and HD are 
neurodegenerative and caused by protein inclusions.  We selected PD prefrontal 
cortex samples that exhibited reported neuron loss on their neuropathological 
evaluation (n=6) and PD samples without reported cortical neuronal loss (n=8). 
From total RNA, RT-qPCR was performed for miR-10b-5p. No difference was 
seen in miR-10b-5p expression when stratifying PD based on the extent of 
neuron loss (t=0.59, p-value=0.58).  Additionally, no significant difference in HD 
miR-10b-5p expression from qPCR was observed when stratifying HD cases 
based on a measure of cortical neuron loss (f=0.28, p-value=0.76). 
Next, the relative expression of miR-10b-5p in PD was compared to all 
nineteen HD and eighteen control samples assayed. While no significant 
difference in miR-10b-5p expression was observed between control and PD 
samples (q=0.05, p=0.99), a significant difference was seen in HD compared to 
PD (q=7.30, p<0.0001; Figure 6), suggesting increased miR-10b-5p expression, 
independent of neuron loss, is not a generalized response to neurodegeneration. 
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Figure 6. miR-10b-5p expression in control, Parkinson's disease and 
Huntington's disease prefrontal cortex. 
Up-regulation of miR-10b-5p was confirmed in HD by performing RT-qPCR, 
comparing nineteen Huntington’s disease prefrontal cortex samples to eighteen 
non-neurological disease control samples (***p<0.001) or fourteen Parkinson’s 
disease samples (***p<0.001). ∆∆CT values of miR-10b-5p in PD and HD as 
compared to controls are shown on the y-axis. The absence of up-regulation in 
PD frontal cortex suggests that up-regulation of miR-10b-5p may be HD specific.  
(CT= cycle threshold; RT-qPCR=reverse transcription quantitative PCR; 
PD=Parkinson’s disease; HD=Huntington’s disease) 	
 
Ectopic miR-10b-5p expression protects HD cell lines from 
polyglutamine-mediated cytotoxicity. To determine the functional importance 
of miR-10b-5p up-regulation in HD, we ectopically expressed miR-10b-5p in 
PC12 Q73 cells. These cell stably expressed huntingtin fragment derived from 
exon 1 (1-90), contain a pathogenic, 73 long polyglutamine repeat and a MYC 
epitope for protein identification. PC12 cells have been shown to terminally 
differentiate and form neural processes upon nerve growth factor (NGF) 
treatment [21], and HD models of these cells have been highly characterized, 
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exhibiting phenotypic changes such as aggregate formation and polyglutamine-
dependent cell death [22-26].  
PC12 Q73 cells were transfected with miR-10b-5p mimic or a negative 
control mimic, cel-miR-67-3p, after 48 hours post-differentiation. Cell survival was 
quantified using a MTT cell viability assay 48 hours post-transfection. Increased 
survival, though modest (53.9% versus 48.2%), was statistically higher for cells 
transfected with miR-10b-5p compared to cells transfected with negative control 
miRNA (q=4.58, p-value<0.0001; Figure 7). The enhanced survival via ectopic 
miR-10b-5p expression was further substantiated in experiments using viable 
fluorescent cell staining, where miR-10b-5p transfected cells showed increased 
cell viability over cells transfected with negative control miRNA (t=2.381, p-
value=0.018). 
 Thus, miR-10b-5p may play a protective role in enhancing cell survival 
during stress. To model stress, we treated miRNA transfected cells with 1uM MG 
132, a potent proteasome inhibitor that increases huntingtin aggregation and 
cellular apoptosis in PC12 HD cell lines [27]. As expected, MG 132 treated cells 
had reduced cell viability as compared to untreated cells (cel-miR-67-3p, q=6.52, 
adjusted p-value<0.0001; miR-10b-5p, q=10.88, adjusted p-value<0.0001). 
However, MG 132 treated miR-10b-5p transfected PC12 Q73 cells exhibited 
improved survival over those transfected with negative control miRNA (q=3.728, 
adjusted p-value=0.045). No statistical difference was observed when comparing 
miR-10b-5p levels with MG 132 treatment to cel-miR-67-3p without treatment, 
		 35	
(q=2.95, adjusted p-value=0.16), suggesting miR-10b-5p may enhance survival 
in times of cellular stress. 
Figure 7. miR-10b-5p overexpressing PC12 Q73 cells exhibit reduced 
cytotoxicity. 
PC12 cells expressing huntingtin exon 1 with a polyglutamine expansion 
spanning 73 repeats were transfected with miR-10b-5p or cel-miR-67-3p as a 
negative control. On day 3 post-differentiation, a subset of cells were treated with 
1 uM MG 132. A MTT assay was used to measure cell viability after four days 
post differentiation. On the Y-axis, the viability percentage was calculated from 
the initial cell count. Error bars represent SEM. (****p<0.0001; **p<0.001 
*p<0.05) 
 
 
 
miRNA expression is related to clinical variables in HD. RNA 
sequence count data may be non-normally distributed [28], and tests of normality 
for miRNA expression levels in HD found that miR-10b-5p was negatively 
skewed (see Materials and Methods). Therefore, to test the relationship of 
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motor symptoms, disease duration and age at death, as well as to the sample 
quality information for RIN/RQN (RNA integrity number/RNA quality number), we 
applied a step-wise backwards selection, negative binomial regression model.  
 Age at onset, duration and age at death are inter-dependent and could not 
be simultaneously included in the models. Furthermore, age at onset and age at 
death were strongly correlated with each other (Pearson r=0.85, p-value=5e-04) 
and both were correlated with CAG repeat size (r=-0.84, p-value =6e-04, and r= -
0.89, p-value =1e-04 respectively) while duration was not correlated with age at 
onset, age at death or CAG repeat size in this sample. To determine which 
variables best modeled the relationship of the miRNAs to clinical variables, we 
compared the Akaike information criterion (AIC) for each variable (onset age, 
death age and duration) in regression analyses that adjusted for the effect of 
CAG repeat size. Of these three variables, duration was found to have the 
poorest fit with each of the five miRNAs and therefore we report analyses 
containing age at onset and age at death.  
 Among the HD brains, CAG repeat size, age at onset and age at death 
were all independently found to have a negative association with miR-10b-5p 
(CAG, β= -0.18, p-value =2.7e-05; onset, β= -0.05, p-value=1.9e-05; death, β= -
0.07, p-value=6.8e-07). CAG repeat size and age at onset were found to be 
independently, negatively related to miR-196a-5p (CAG, β= -0.15, p-value=1.7e-
02; onset, β=-0.07, p-value=1.4e-03). Age at death was significantly related to 
miR-615-3p expression (β= -0.03, p-value=0.0045) and age at onset was 
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associated with miR-196b-5p (β= -0.04, p-value=9e-04). No association to any 
clinical features was seen for miR-1247-5p. In order to fully evaluate whether 
there was any effect of disease duration on the observed relationships to the 
clinical features, duration was added back into final models.  No substantial 
changes to the effect estimates were observed with the addition of duration to 
any of the models. 
None of the miRNA levels was related to post-mortem interval in either 
control or HD case samples. The essentially null level of expression in controls 
prevented meaningful assessment of the relationship of miR-196a-5p, miR-196b-
5p and miR-615-3p with clinical variables, in particular age at death, or sample 
variables, post-mortem interval (PMI), or RIN/RQN. Analysis of miR-10b-5p 
showed no association to age at death (β=-0.002, p-value=0.60), or PMI (β=-
0.014, p-value=0.31), but did show association with RIN/RQN (β=0.54, p-value= 
7.2e-05) in controls. miR-1247-5p showed association with later age at death 
(β=-0.013, p-value=0.024) in controls.  
Expression of miR-10b-5p, miR-196a-5p, miR-196b-5p and miR-615-
3p are correlated. Among the twelve HD samples, the levels of four out of the 
five significantly differentially expressed miRNAs (miR-10b-5p, miR-196a-5p, 
miR-196b-5p, miR-615-3p) were strongly correlated with each other, (Spearman 
r range 0.71-0.88; p range 0.0002-0.01). miR-1247-5p was not significantly 
correlated with these miRNAs (Spearman r range 0.13-0.51; p range 0.09-0.70). 
Because the values of miR-615-3p and miR-196a-5p were essentially zero in the 
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control samples, correlations among the miRNAs were not performed for 
controls. 
mRNA targets of miR-10b-5p, miR-196a-5p, miR-196b-5p and miR-
615-3p may have similar functions. Watson-Crick base-pairing between 
nucleotide position 2 through 8 on the mature miRNA, termed the ‘seed region,’ 
and the 3’ untranslated region (3’ UTR) of target mRNA determine the 
recognition, specificity and efficiency of miRNA silencing [29]. Seed sequences 
differ for miR-10b-5p (ACCCUGU), miR-615-3p (CCGAGCC) and miR-1247-5p 
(CCCGUCC) suggesting these miRNA have different targets, while miR-196a-5p 
and miR-196b-5p share a seed sequence (AGGUAGU) and only differ by a 
single base difference in mature miRNA sequence.  
 Targets of the five miRNAs were obtained from miRWalk 
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html), a repository of 
experimentally validated miRNA targets curated from literature and online 
resources [30]. miRWalk targets of miR-196a, miR-196b and miR-1247 were not 
strand specific. The miRWalk database contained 84 unique targets for miR-10b-
5p, 80 for miR-196a, 40 for miR-196b, two for miR-1247 and twelve for miR-615-
3p. Since miR-1247 had just two validated targets, it was removed from analysis.  
 Four target genes (DICER1, HOXA7, HOXB4, HOXD1) were shared 
across all four miRNAs. miR-10b-5p shared eleven targets with miR-196a-5p 
(HOXB8, COX8A, HOXA10, NPC1, FLT3, AKT1, NPM1, DROSHA, AGO2, 
NFYC, PAX7), and one with miR-615-3p (MAPK8). miR-196a and miR-196b 
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shared 28 targets. In all, eleven of the 167 unique validated targets were Hox 
cluster genes (HOXA1, HOXA7, HOXA9, HOXA10, HOXB4, HOXB7, HOXB8, 
HOXC8, HOXD1, HOXD4, HOXD10). 
To understand the influence these miRNAs may be having on shared 
biological processes, targets of each miRNA were analyzed using IPA Core 
Analysis. To find overlap in biological functions and canonical pathways of each 
miRNA and its targets, the IPA Core Comparison Analysis tool was used. After 
correcting for multiple comparisons, targets of miR-10b-5p, miR-196a, miR-196b 
and miR-615-3p shared significant overlap in 33 biological functions; the top 
three functional categories were “Cell Death and Survival,” (Benjamini-Hochberg 
adjusted p-value, range=3.5e-07 – 1.5e-04), “Nervous System Development and 
Function” (range=1.5e-07 – 1.5e-03) and “Cellular Assembly and Organization” 
(range=2.5e-05 – 1.7e-03). Twelve pathways were shared among all four sets of 
miRNA targets, including “Huntington’s Disease Pathway” (range=7.6e-04 – 
8.1e-03), (Gene set=AKT1, BAX, CAPSN1, CLTC, CREB1, EGFR, HDAC9, JUN, 
MAPK8).  
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Table 4. 22 differentially expressed targets of miR-10b-5p, miR-196a, miR-
196b, miR-1247 and miR-615-3p. 
* FDR-adjusted q-value for 167 targets of the five miRNAs.  		
	
 
 
mRNA targets of differentially expressed miRNAs are differentially 
expressed. Total mRNA-sequencing was performed in the same brain samples 
as miRNA-sequencing to examine whether gene expression was affected by 
miRNA up-regulation. Of the 169 unique gene targets for the five differentially 
expressed miRNAs, 167 were detected using mRNA-sequencing. 22 mRNA 
targets were significantly differentially expressed between the HD and control 
prefrontal cortex samples (False Discovery Rate (FDR) adjusted q-value=0.05 
Target gene miRNA Location
Mean Control 
Expression 
(n=9)
Mean HD 
Expression 
(n=12)
Fold Change p-value q-value *
SERPINE1 miR-10b-5p 7q22.1 22.91 140.82 6.15 3.03E-11 5.06E-09
CDKN1A miR-196a 6p21.2 336.73 841.75 2.5 1.58E-04 1.22E-02
HOXD4 miR-10b-5p 2q31.1 1.74 18.33 10.51 2.38E-04 1.22E-02
ANXA3 miR-10b-5p 4q21.21 259.93 553.71 2.13 2.92E-04 1.22E-02
TWIST1 miR-10b-5p 7p21.2 43.43 105.16 2.42 5.63E-04 1.72E-02
CD33 miR-196a, miR-196b 19q13.3 16.58 46.63 2.81 6.75E-04 1.72E-02
DIO3 miR-1247 14q32 10.89 41.93 3.85 7.29E-04 1.72E-02
MMP2 miR-10b-5p 16q13-q21 58.67 137.83 2.35 8.26E-04 1.72E-02
MMP9 miR-10b-5p 20q11.2-q13.1 5.32 17.33 3.26 9.33E-04 1.73E-02
HOXA10
miR-10b-5p, 
miR-196a, 
miR-196b
7p15.2 1.06 17.06 16.12 1.21E-03 1.73E-02
RHOD miR-10b-5p 11q14.3 12.71 37.96 2.99 1.23E-03 1.73E-02
COL1A1 miR-196a 17q21.33 30.19 220.28 7.3 1.31E-03 1.73E-02
HLA-E miR-10b-5p 6p21.3 3703.47 7769.76 2.1 1.34E-03 1.73E-02
PPARA miR-10b-5p 22q13.31 444.7 865.02 1.95 1.53E-03 1.73E-02
PAX6 miR-196a 11p13 693.52 1337.23 1.93 1.62E-03 1.73E-02
EGFR miR-10b-5p 7p12 784.95 1762.88 2.25 1.66E-03 1.73E-02
HOXB7 miR-196a 17q21.3 1.63 6.99 4.28 2.83E-03 2.78E-02
PLAUR miR-10b-5p 19q13 56.15 119.67 2.13 3.65E-03 3.38E-02
HOXD10 miR-10b-5p 2q31.1 1.25 9.33 7.45 4.73E-03 3.96E-02
RUNX1 miR-10b-5p 21q22.3 87.69 224.88 2.56 4.74E-03 3.96E-02
SOX2 miR-10b-5p 3q26.3-q27 1963.76 3492.72 1.78 5.32E-03 4.23E-02
KRT5 miR-196a 12q13.13 113.74 51.99 -2.19 6.00E-03 4.55E-02
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after adjusting for 167 comparisons). Only one gene (keratin 5, KRT5) was down-
regulated in HD (Table 4), and four of these target genes were located in the Hox 
clusters (HOXD4, HOXA10, HOXB7 and HOXD10).  
 
Table 5. Differential expression of Hox cluster genes in HD. 
* FDR-adjusted q-value for the 55 genes in the four Hox clusters 
 
 
 
miR-10b-5p, miR-196a-5p, miR-196b-5p and miR-615-3p expression is 
related to Hox cluster gene expression. Four of the five up-regulated miRNAs 
are located intergenic to Hox gene clusters (Figure 8). Because of gene 
duplication, miR-196a is derived from both the HOXB and HOXC clusters; miR-
10b is located in the HOXD cluster and miR-615 is found in the HOXC cluster 
Mean 
Control 
Expression
Mean HD 
Expression
(n=9) (n=12)
HOXA11 1.06 8.2 7.75 3.96E-05 2.07E-03
HOXA5 1.06 7.63 7.21 1.03E-04 2.07E-03
HOXD8 1.15 7.84 6.8 1.13E-04 2.07E-03
HOXD4 1.74 18.33 10.51 2.38E-04 3.22E-03
HOXB9 1.06 9.2 8.69 2.93E-04 3.22E-03
HOXA10 1.06 17.06 16.12 1.21E-03 1.11E-02
HOXC6 1.15 6.16 5.34 1.62E-03 1.27E-02
HOXA11-AS 1.25 7.39 5.9 2.49E-03 1.71E-02
HOXB7 1.63 6.99 4.28 2.83E-03 1.73E-02
HOXA13 1.45 8.74 6.03 4.07E-03 2.24E-02
HOXD10 1.25 9.33 7.45 4.73E-03 2.36E-02
HOXD1 55.91 22.8 -2.45 8.55E-03 3.92E-02
HOXC10 1.36 8.04 5.9 1.06E-02 4.14E-02
HOXC4 3.57 10.77 3.02 1.12E-02 4.14E-02
HOTAIRM1 3.52 12.52 3.56 1.13E-02 4.14E-02
Gene Fold Change p-value q-value *
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[31,32]. A total of 55 genes (40 protein-coding genes, eleven antisense 
transcripts, three functional lncRNAs and one pseudogene) are located in the 
four Hox clusters [33,34]. To evaluate evidence for a general regional up-
regulation of Hox cluster genes, an expression analysis of the mRNA-sequence 
data was performed for all annotated genes within the Hox loci (Table 5). Fifteen 
out of 55 genes within the Hox loci were differentially expressed in HD. Fourteen 
Hox genes were significantly up-regulated (FDR-adjust q-value<0.05, mean fold-
change = 6.73, range 3.02 to 16.12) and a single Hox gene was down-regulated 
(HOXD1, FDR-adjust q-value=3.92e-02, fold change = -2.45). The majority of 
differentially expressed Hox genes (13 out of 15) were essentially unexpressed in 
controls.  
 The genes adjacent to the four differentially expressed miRNAs were 
highly expressed. Two genes immediately adjacent to miR-10b-5p were 
significantly up-regulated in HD (HOXD4, FDR-adjusted q=3.22e-03; HOXD8, 
FDR-adjusted q=2.07e-03), (Figure 8). HOXB9 (FDR-adjusted q-value=3.22e-
03) immediately downstream of miR-196a-1 and HOXC10 (FDR-adjusted q-
value=4.14e-02) immediately upstream of miR-196a-2 were also up-regulated. 
Furthermore, all three Hox genes located upstream of miR-196b were 
significantly up-regulated in HD (HOXA10, FDR-adjusted q-value=1.11e-02; 
HOXA11, FDR-adjusted q-value=2.07e-03; HOXA13, FDR-adjusted q-
value=2.24e-02). HOXC6 (FDR-adjusted q-value=1.27e-02) immediately 
upstream of miR-615 was also up-regulated.  
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Figure 8. Differentially expressed miRNAs in HD are located in Hox gene 
clusters. 
Schematic representation of Hox clusters. Hox genes are represented as 
numbered boxes (labeled 1-13), miRNA are represented by triangles and other 
genes in the regions (functional lncRNA, PRAC) are represented by rectangles. 
Antisense transcripts and pseudogenes are not pictured. Nineteen genes within 
Hox cluster regions were found significantly differentially expressed in HD 
prefrontal cortex using mRNA-sequencing (FDR-adjusted p-value<0.05). Four 
miRNAs, one lncRNA, and fourteen Hox genes were significantly up-regulated in 
HD (indicated by red), many of which are adjacent to differentially expressed 
miRNAs. A single Hox gene (HOXD1) was down-regulated in HD (indicated by 
blue) (HD=Huntington’s disease). 	
 
Discussion 
Up-regulation of expression for five miRNAs in HD brain. We report a next-
generation sequencing study of small RNAs, identifying 1,417 mature miRNA 
species in the prefrontal cortex (Brodmann Area 9) of twelve HD and nine control 
brains. Five of these, miR-10b-5p, miR-196a-5p, miR-196b-5p, miR-615-3p and 
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miR-1247-5p, were up-regulated in HD at genome-wide significance (FDR q-
value <0.05), and three of these five, miR-196a-5p, miR-196b-5p and miR-615-
3p, were expressed at near zero levels in the control brains. Up-regulation of 
miR-10b-5p was validated in the miRNA-sequencing samples and confirmed in 
an independent replication sample set. Several studies implicating a role for 
miRNAs in HD have been performed, although, to our knowledge this is the first 
genome-wide quantification of miRNA expression comparing individual human 
HD and control brain samples.  
 Packer et al. [11], studying an array of 365 mature miRNAs, had 
previously reported miR-196a-5p to be significantly increased by nearly six-fold in 
Brodmann Area 4 of HD grade 1 brains. Recently, a study by Cheng et al. [13] 
found increased miR-196a expression suppressed mutant HTT expression in 
both HD neuronal cell models and HD transgenic mouse models. These findings 
suggest increased expression of miR-196a may be an adaptive response, 
promoting neuronal survival and may have therapeutic implications for HD. 
Miyazaki et al. [35] studied miR-196a in spinal and bulbar muscular atrophy 
(SBMA), a neurodegenerative disease caused by a similar polyglutamine repeat 
expansion in the androgen receptor (AR) gene. They found increased miR-196a 
expression via adeno-associated virus vector-mediated delivery reduced AR 
mRNA levels leading to improved neurological function in transgenic SBMA 
mouse models. Together, these findings suggest a neuroprotective role for miR-
196a and its targets and possible therapeutic implications across multiple 
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polyglutamine-expansion neurodegenerative diseases. miR-196a-5p and miR-
10b-5p were among the 56 miRNAs found to be elevated in response to mutant 
HTT over-expression in undifferentiated NT2 cells [36]. According to the miRNA 
search program “PubmiR,” [37] miR-196b-5p, miR-1247-5p and miR-615-3p 
have not been previously reported in HD miRNA studies. 
 A number of past studies have examined miRNA levels in HD, HD 
transgenic mice or cellular models; however, we did not replicate the results 
obtained in these studies. Gaughwin et al. [36] reported miR-34b elevated in 
plasma samples in HD, but we found neither miR-34b-3p nor miR-34b-5p to be 
altered in HD brain at genome-wide levels. We were not able to confirm any of 
the miRNAs reported in past microarray studies that examined targeted subsets 
of miRNAs, including the nine miRNAs reported as down-regulated in two mouse 
models of HD (YAC128 and R6/2) by Lee et al. [14] using a 567 miRNA 
microarray or the 38 miRNAs with altered expression in HD transgenic mice in a 
382 miRNA microarray [15]. Johnson et al. [10-12] reported miR-29a and miR-
330 to be significantly up-regulated in HD samples, neither of which was found to 
be altered in this study [10]. In a RT-qPCR study comparing 90 miRNAs in 
mouse Hdh (Q111/Q111) striatal cells to control mice [12,38], none of the 27 
reported differentially expressed miRNAs was different at genome-wide levels in 
our study. The most commonly reported altered miRNA in HD studies, miR-132, 
has been reported as both down-regulated [10,14,39] and up-regulated [11], but 
was not differentially expressed in our study.  
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 While some of the lack of concordance may be a consequence of the 
differences between human and animal models of HD, it is also likely that some 
of the differences are a consequence of the different technologies employed by 
these studies.  Microarrays may have different levels of detection for some 
miRNAs from that seen by miRNA sequencing.  Finally, nearly all of the studies 
employ microarray methods.  Microarrays that study only 365 (e.g. Packer et al. 
[11],) to 567 miRNAs (e.g. Lee et al. [14]) are not performing as many contrasts 
and thus do not adjust for as many contrasts as our genome wide analysis (e.g. 
1,417 miRNAs detected) demands.  
miR-10b-5p, miR-196a-5p, miR-196b-5p and miR-615-3p implicate 
Hox cluster genes. Four (miR-10b-5p, miR-196a-5p, miR-196b-5p and miR-
615-3p) of the five differentially expressed miRNAs are related to Hox cluster 
genes as follows: (1) these four are located in intergenic regions of the Hox 
clusters, (2) eleven Hox genes are validated targets of these four miRNAs, (3) 
Hox genes adjoining differentially expressed miRNAs are differentially expressed 
and (4) multiple Hox cluster genes are differentially expressed in HD versus 
control brains (Table 4). 
 Of the eleven Hox gene targets, eight did not differ in their expression 
across condition. A single target, HOXD1 was seen to be down-regulated in HD 
(FC=-2.45). HOXD1 is a reported target of four of the five miRNAs [40] which 
may explain its repression in HD.  
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 Three Hox gene targets were up-regulated in HD (HOXB7, HOXD4 
HOXD10). It is possible these up-regulated Hox genes share similar regulatory 
mechanisms, as the increased miRNA expression does not produce the 
expected miRNA-mediated gene silencing and suppress the observed up-
regulation of the miRNA target genes. Coevolution of Hox genes and Hox-related 
miRNAs may further suggest that they share regulatory elements or mechanisms 
[41]. Furthermore, Hox genes and related miRNAs have been observed to have 
similar patterns of transcriptional activation and both are activated by retinoic 
acid [42-46]. Although miR-10b-5p has been validated as targeting HOXD4, they 
may exhibit patterns of co-expression. Specifically, Phua et al. [45] report miR-
10b and HOXD4 are temporally co-expressed during neurodifferentiation. Here, 
we see a similar up-regulation and co-expression pattern in HD, where miR-10b 
and HOXD4 are both highly expressed. 
 Hox genes are a family of transcription factors that contribute to major 
morphological changes during embryonic development and are required for 
anterior-posterior body axis in bilaterally developing species [47]. They are highly 
involved in most aspects of early development, and are prominently expressed in 
the developing brain [48]. Hox-related miRNAs may also follow similar spatio-
temporal patterns of expression during embryogenesis [49].  
 Hox genes are regulated by retinoic acid but also other factors, including 
basic fibroblast growth factor [50], steroid hormones [51,52] and polycomb 
repressive complex group [53]. Polycomb group (PcG) proteins assemble into 
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large silencing complexes and control histone-modifying activity. Hox genes are 
repressed by PcG complexes, specifically Polycomb Repressive Complex 2 
(PRC2), which trimethylates histone H3 at lysine 27 (H3K27me3) [53].  
Seong et al [54] observed knockout huntingtin mouse embryos lacked repression 
of HOXB1, HOXB2, and HOXB9 and showed diminished global H3K27me3, 
while a knock-in expanded repeat mouse exhibited increased H3K27me3 signal, 
suggesting mutant huntingtin may alter proper PRC2 activity. These findings 
raise the possibility that the increased expression of miRNAs and Hox genes 
reported here are related to enhanced H3K27me3 or impaired PcG repression. 
However, the role of Hox in the adult, HD brain is still unclear.  Increased 
transcriptional activity of Hox may be compensatory, helping to preserve or re-
establish cell polarity, or an indirect result of impaired epigenetic regulation. 
miR-10b-5p response in HD may be protective. To functionally validate 
our miRNA-sequencing findings, we chose to assess miR-10b-5p. We believed 
this miRNA to be the most biologically active of the differentially expressed 
miRNAs. miR-10b-5p had the highest basal expression levels and the highest 
fold change between conditions. Additionally, miR-10b-5p levels were not 
increased in PD, a comparable protein aggregate, neurodegenerative disease, 
nor in PD samples with pathology in the prefrontal cortex equivalent to HD.  
 To determine whether miR-10b-5p had a protective or deleterious effect 
on neuron viability, we ectopically expressed miR-10b-5p in terminally 
differentiated PC12 Q73 cells. Since the levels the five differentially expressed 
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miRNA were up-regulated, we felt overexpression of miR-10b-5p best 
represented the phenotype observed in HD brain.  
 We reported increased miR-10b-5p expression enhanced the survival of 
PC12 Q73 cells.  Furthermore, we found that increased miR-10b-5p expression 
enhanced survival in the presence of apoptosis-inducing compound, MG 132. In 
this experiment, survival in cells with increased miR-10b-5p expression was 
comparable to that of unchallenged cells and significantly greater than untreated 
cells exposed to toxin.  These finding provide support for the hypothesis that 
increased miR-10b-5p may be a neuroprotective response to the expanded 
polyglutamine repeat seen in HD and speaks to the role of this microRNA in the 
pathology of HD.  
miR-10b-5p, miR-196a-5p, miR-196b-5p and miR-615-3p have 
overlapping biological functions.  pathway analysis, we showed that miR-10b-
5p, miR-196a-5p, miR-196b-5p and miR-615-3p targeted genes are predicted to 
be involved in apoptosis as well as nervous system development and function. In 
neuroblastoma SH-SY5Y cell lines, miR-10a, miR-10b and miR-615-5p 
expression levels significantly increased during all-trans-retinoic-acid (ATRA) 
treatment, indicating miR-10a/b and miR-615-5p may have a role in 
neurodifferentiation [44]. SH-SY5Y cells treated with antisense miR-10a or miR-
10b had impaired neurite outgrowth and morphology but did not show changes in 
overall cell proliferation [44]. miR-10a and miR-10b were highly expressed in SK-
N-BE, LAN5 and SH-SY5Y cell lines during ATRA treatment and ectopic 
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expression of miR-10ab mirrored the phenotype of the ATRA treatment [42]. 
Taken together, these studies implicate these miRNAs in neuron differentiation, 
migration, and outgrowth.  
In our past studies [16], we found increased neurite outgrowth in HD 
prefrontal cortex. Relative to controls, HD pyramidal neurons had a significantly 
increased number of primary dendritic segments, increased total dendritic length, 
and more dendritic branches than control neurons. Here, we report four miRNAs 
that have been observed in cell models to present a similar phenotype. It is 
possible that increased expression of these miRNAs and related targets 
represent an adaptive response of neurons stressed by a toxic expanded 
polyglutamine protein fragment. 
miR-10b-5p, miR-196a-5p, miR-196b-5p and miR-615-5p are related to 
HD pathogenesis. Four of the five up-regulated miRNAs showed association to 
clinical features of HD (CAG repeat size, age of motor onset and age at death for 
miR-10b-5p; CAG repeat size and age at onset for miR-196a-5p, age at onset for 
miR-196b-5p and age at death for miR-615-3p). Due to the near zero level of 
expression in controls, it was not possible to assess the relationship of miR-
196a-5p, mir-196b-5p and miR-615-3p to age at death, but miR-10b-5p was not 
correlated with age at death in controls. Thus, the increased expression of these 
miRNAs did not appear to be related to normal aging, but rather a component of 
gene regulation and transcription in the context of neurodegeneration. A growing 
body of literature points to the presence of toxic effects of the HD gene 
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substantially before the onset of symptoms, perhaps from the time of conception 
[55-57].  
 Because age at death represents the lifetime exposure of the individual to 
the effects of the HD gene, we hypothesize that the association of miR-10b-5p 
and miR-615-3p with age at death may represent the lifetime exposure to the 
effects of the HD mutation. If the relationship of altered miRNA expression to age 
at death supports the view that the HD gene may have a life-long effect among 
expanded CAG-repeat carriers, this raises the possibility that the HD mutation 
may influence neuronal development in the developing brain through the action 
of one or more of these miRNAs and Hox cluster genes.  
Target genes of over-expressed miRNAs show increased expression 
in HD. We report five miRNAs as being highly up-regulated in HD and though our 
expectation was to see the mRNA targets of these miRNAs as decreased, we 
observe increased expression of many of their shared mRNA targets. We believe 
these effects are not attributable to differences in cell populations studied, since 
flow cytometric analysis measuring neuron abundance found no significant 
difference across condition. Rather, we hypothesize positive miRNA-mRNA 
target relationships are a result of HD-specific alterations in mRNA processing.  
Translation is a highly dynamic process. Cytoplasmic mRNA actively engaged in 
translation can cycle to a non-translated state and accumulate in stress granules 
or processing bodies (P-bodies). During cellular stress, mRNA can be 
sequestered to P-bodies or stress granules, to stall translation through 
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translational repression machinery or miRNA silencing, until stress conditions 
have been resolved [7,58-60]. P-bodies may also serve an important role in RNA 
transport. Because neurons are highly polarized, cytoplasmic transport of mRNA 
is essential for localized translation to discrete regions of the cell.  During 
transport, it is believed that mRNAs are silenced by miRNA, upon rapid 
exchange at the synapse [60-62]. 
In HD cortical neurons, excitotoxicity, oxidative damage, aberrant gene 
expression and energetic defects lead to stress conditions and in response, cells 
may sequester mRNA to P-bodies and stress granules. Among the 55 Hox locus 
genes studied, only one of the fifteen significantly differentially expressed genes 
is down regulated (Table 4). Thus, the increased levels of most of the validated 
gene targets of these four miRNAs may be reactionary, as they are sequestered 
to P-bodies for storage as part of a protective process to enhance cell viability 
[7].   
To the best of our knowledge, no study has addressed the role of P-
bodies or stress granules in HD. However, it was observed in live cortical 
neurons that wildtype huntingtin co-localized in P-bodies, specifically in neuronal 
RNA granules, along with Argonaute 2, the endonuclease required for RNA-
mediated gene silencing by the RNA-induced silencing complex (RISC) [63,64]. 
Therefore, it is reasonable to suggest mutant huntingtin may impair miRNA-
mediated mRNA degradation and/or localized translation of specific mRNAs. 
		 53	
There is evidence that miRNA-mRNA regulatory mechanisms may be altered in 
other neurodegenerative diseases as well. In a joint examination of miRNA-
mRNA expression in Alzheimer’s disease (AD) and control prefrontal cortex, an 
overwhelming number of miRNA to mRNA targets were found to be positive 
correlated.  Genomic variants in TDP-43 and FUS, genes that encode stress 
granule proteins, were found to cause familial Amyotrophic lateral sclerosis 
[65,66] and several other stress granule proteins (TIA-1, G3BP) may also be 
pathogenic [67].  
miRNAs as potential biomarkers in HD. These studies suggest potential 
relationships of these miRNAs to CAG repeat expansion, age at onset or age at 
death. If these findings hold up on further examination, these miRNAs may hold 
potential to provide insight into important biological and disease expression for 
HD. miRNA are extremely stable. The half-life of the majority miRNAs has been 
predicted to be on average five days and plasma miRNAs have been found to be 
stable after being subjected to high heat, extreme pH, long-time storage at room 
temperature, or multiple freeze-thaw cycles [68-70]. If these miRNAs cross the 
blood-brain barrier and can be detected at reasonable levels in serum/plasma 
from mutant HD gene carriers, they may serve as biomarkers of disease 
expression.  
Materials and Methods 
Sample Information. Frozen brain tissue from prefrontal cortex 
Brodmann Area 9 (BA9) was obtained from the Harvard Brain and Tissue 
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Resource Center (HBTRC) McLean Hospital, Belmont MA. Twelve Huntington's 
disease (HD) samples and eleven neurologically-normal control samples were 
selected for the study (Table 1). The HD subjects had no evidence of Alzheimer 
or Parkinson disease (PD) comorbidity based on neuropathology reports. For 
microscopic examination, 16 tissue blocks were systematically taken and 
histologically assessed as previously described [3]. All samples were male. HD 
samples and controls were not different for postmortem interval (PMI) (t=1.07, 
p=0.30), RNA integrity number (RIN) (t=0.83, p=0.41) or death age (t=0.40, 
p=0.69). CAG repeat size was known for all HD samples and onset age and 
disease duration was unknown for a single sample (Table 1). Eight additional 
HD, nine control and fourteen PD cases were studied as part of validation and 
replication studies, and were obtained from the HBTRC and the Sun Health 
Research Institute Sun City, Arizona. 
RNA extraction. Total RNA, for all samples studied, was isolated using 
QIAzol Lysis Reagent and purified using miRNeasy MinElute Cleanup columns 
(Qiagen Sciences Inc., Germantown, MD). RNA quality for sequencing was 
assessed using either Agilent’s BioAnalyzer 2100 system and RNA 6000 Nano 
Kits to find RNA Integrity Number (RIN) or Agilent 2200 TapeStation and DNA 
ScreenTape assay RNA Quality Number (RQN; Agilent, Foster City, CA). Both 
methods calculate the area under the peak for 18S and 28S RNA as a ratio of 
total RNA as well as the relative height of the 18S and 28S peaks to determine 
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RNA quality [71]. The RIN/RQN values were similar for the twelve HD and eleven 
control specimens studied for miRNA and mRNA (t=0.95, p=0.36). 
Illumina miRNA sequencing (miRNA-seq). For each brain sample, 1 ug 
of RNA was used to construct sequencing libraries using Illumina’s TruSeq Small 
RNA Sample Prep Kit, according to the manufacturer’s protocol (Illumina, San 
Diego, CA). In brief, small RNA molecules were adapter-ligated, reverse 
transcribed, PCR amplified and gel purified to generate the library. Multiplexed 
samples were equimolarly pooled into sets of eight samples per flowcell lane and 
sequenced using 1x50 bp single-end reads on Illumina’s HiSeq 2000 system at 
Tufts University sequencing core facility (http://tucf-genomics.tufts.edu/). 
Demultiplexing and FASTQ file generation (raw sequence read plus quality 
information in Phred format) were done using Illumina’s Consensus Assessment 
of Sequence and Variation (CASAVA) pipeline. 
Primary processing of Illumina miRNA-seq reads. Sequence read 
quality was evaluated using the FASTQ quality filter module from the FASTX-
toolkit version 0.0.13 (http://hannonlab.cshl.edu/fastx_toolkit/), and only those 
reads with at least 80% of the base calls above Q20 (Phred score) were retained. 
The 3’ adapter sequence (5’-TGGAATTCTCGGGTGCCAAGG-3’) was removed 
from all reads using the FASTA/Q clipper module from the FASTX-toolkit. A 
minimum length threshold of 15 nucleotides was set for clipped reads because 
miRNAs of this length will contain the seed sequence. To avoid redundancy 
amongst identical read species, the reads were collapsed using the FASTA/Q 
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collapser module from FASTX-toolkit to generate a FASTA file of only the unique 
read species.  
Alignment and mapping of miRNA-seq reads. Quality-filtered, 3’ 
adapter-clipped reads were aligned to the UCSC human reference genome (build 
hg19) using Bowtie version 0.12.3 [72]. Alignment parameters were set to allow 
for no mismatch alignments and no limits on multiple mapping instances. 
Multiple-mapped identical sequences were summed for a single count for that 
annotated mature miRNA. The default settings were used for all other alignment 
options.  
 The miRNA aligned data are available on ArrayExpress as follows:  
Experiment name: RNA-seq of micro RNAs (miRNAs) in Human prefrontal cortex 
to identify differentially expressed miRNAs between Huntington's Disease and 
control brain samples.  ArrayExpress accession: E-MTAB-2206, Release date: 
2014-01-30 https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-2206/ 
miRNA abundance estimation. Aligned reads that overlapped with the 
human miRNA annotation version 19 from miRBase 
(http://www.mirbase.org/ftp.shtml) were identified using default BEDTools’ 
IntersectBed functionality [73]. To select for mature miRNA reads, sequences 
more than 27 bases in length were removed. Only those reads for which the 
aligned 5’ start-nucleotide matched exactly to the 5’ start-nucleotide of the 
annotated miRNA were retained for the analysis. After filtering, collapsed read 
counts were summed per annotated mature miRNA. 
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miRNA differential expression. The R (http://www.R-project.org) 
package DESeq version 1.10.1 [28] was used to perform the differential 
expression analysis between HD and control samples using the read counts 
generated for each sample as described above. miRNAs with zero read counts 
across all case and control samples were removed from analysis. To 
accommodate the analysis of miRNAs with read counts of zero for some samples, 
a pseudo-count of one was added to all raw counts for every miRNA across all 
the samples, prior to performing DESeq’s estimateSizeFactors and 
estimateDispersions functions with default options. DESeq assumes that count 
data follow a negative binominal distribution and factors in technical and 
biological variance when testing for differential gene expression between groups. 
DESeq’s function, estimateSizeFactors, was used to obtain normalization factors 
for each sample and to normalize miRNA read counts.  
 The normalized counts were evaluated by principal component analysis 
(PCA) with the FactoMineR R package for all HD and control samples. The 
samples identified to be three or more standard deviations away from the mean 
on the first or second principal component were considered outliers and were 
removed from analysis. The first two principal components were used because 
they each explained more than 10% of the variance, while the remaining principal 
components explained less than 10% of the variance. Two control samples (C-35 
and C-37) were identified as outliers based on PCA analysis.  
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 miRNA differential expression analysis was performed with DESeq’s 
nbinomTest function for the remaining nine control and twelve HD samples. All 
analyses were performed on DESeq normalized counts.  
miRNA quantitative PCR. miRNA were assayed using Exiqon’s miRCURY LNA 
Universal RT miRNA PCR following the manufacturer’s protocol (Exiqon Inc, 
Denmark). In brief, reactions were incubated for 60 min at 42˚C followed by heat-
inactivation of reverse transcription for 5 min at 95˚C and stored at 4˚C. After 
cDNA synthesis, samples were diluted to 0.2 ng/ul in water. Brain samples were 
assayed using Exiqon ExiLENT SYBR Green master mix and LNA primer sets 
containing UniRT and miR-10b-5p, miR-196a-5p, miR-196b-5p, miR-615-3p or 
miR-1247. Reference primer hsa-SNORD48 PCR/UniRT was used for brain 
samples; U6 snRNA for cell lines. Samples were run in triplicate for each primer 
set in 384-well format (5 ul PCR Master mix, 1ul PCR primer mix, 4 ul 0.2 ng 
cDNA). Reactions were cycled using Applied Biosystems 7900HT Fast Real-
Time PCR System using manufacturer’s instructions (Life Technologies, 
Carlsbad, CA). For analysis, threshold cycle (CT) was generated by ABi SDS 
v2.4 software. CT values for triplicate wells were normalized by average RNU48 
value for brain or U6 for cells. miRNA fold change was calculated using the 2-
ΔΔCT method [74]. 
Neuron abundance quantification. 0.5-1.0 g of tissue in 5 ml of lysis 
buffer was homogenized using a dounce tissue grinder. Lysates were transferred 
to ultracentrifugation tubes, loaded on top of sucrose solution and centrifuged at 
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24,400 RPM for 2.5 hr at 4°C (Beckman Coulter, Pasadena, CA; L8-70 M with 
SW80 rotor). Nuclei pellets were resuspended in 500 ul PBS and incubated at 
4°C in a staining solution containing 0.72% normal goat serum, 0.036% BSA, 
1:1200 anti-NeuN (Millipore, Germany), 1:1400 Alexa488 goat anti-mouse 
secondary antibody (Life Technologies, Carlsbad, CA), for 45 min. Flow 
cytometry was performed at the Boston University Medical School Flow 
Cytometry Core Lab on a FACSVantage SE flow cytometer.   
Illumina messenger RNA sequencing (mRNA-seq). For each brain 
sample, 1 ug of RNA was used to construct sequencing libraries using Illumina’s 
TruSeq RNA Sample Prep Kit according to the manufacturer’s protocol. In brief, 
mRNA molecules were polyA selected, chemically fragmented, randomly primed 
with hexamers, synthesized into cDNA, 3’ end-repaired and adenylated, 
sequencing adapter ligated and PCR amplified. Each adapter-ligated library 
contained one of twelve TruSeq molecular barcodes. Multiplexed samples were 
equimolarly pooled into sets of three samples per flowcell lane and sequenced 
using 2x100 bp paired-end reads on Illumina’s HiSeq 2000 system at Tufts 
University sequencing core facility (http://tucf-genomics.tufts.edu/). 
Demultiplexing and FASTQ file generation were accomplished using Illumina’s 
CASAVA pipeline. 
Primary processing of Illumina mRNA-seq reads. Forward and reverse 
sequencing reads were independently quality-filtered using the FASTQ quality 
filter module from the FASTX-toolkit version 0.0.13 
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(http://hannonlab.cshl.edu/fastx_toolkit/) with the same criteria as that applied for 
the processing of the miRNA-seq reads. Reads failing the quality threshold, as 
well as their corresponding mate reads, were removed. 
Alignment and mapping of mRNA-seq reads. Quality-filtered paired-
end reads were aligned to the UCSC human reference genome (build hg19) 
using TopHat version 2.0.4 [75,76]. This version of TopHat incorporates the 
Bowtie version 2.0.0.7 algorithm to perform the alignment [72] as well as 
SAMtools version 0.1.18.0 for alignment file formatting [77]. For efficient read 
mapping, TopHat requires the designation of the mean and standard deviation of 
the distance between paired-end reads, the read inner-distance. To estimate the 
appropriate read inner-distance, we aligned a subset of 5 million reads from four 
HD and four control samples to the Ensembl human reference transcriptome 
(release 66) using Bowtie version 2.0.0.7. Using the CollectInsertSizeMetrics 
function from picardTools version 1.76 
(http://sourceforge.net/projects/picard/files/picard-tools/), we estimated the 
average mean inner-distance per condition and subsequently applied these 
values for the TopHat alignment; 22 for HD samples 25 for controls respectively, 
(the current TopHat default setting is 20). To account for read variability, the 
standard deviation for inner-distance was set to 100. The number of allowed 
splice mismatches was set to 1. Default settings were used for all other 
alignment options.  
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mRNA gene abundance estimation. Gene expression quantification was 
performed using htseq-count version 0.5.3p9 (http://www-
huber.embl.de/users/anders/HTSeq) and the GENCODE version 14 annotation 
gtf file as reference (http://www.gencodegenes.org/releases). Intersection non-
empty mode and unstranded library type were specified as parameters for htseq-
count. Default settings were used for all other options. 
mRNA differential expression analysis. The mRNA differential 
expression analysis between HD and control samples was performed using 
DESeq version 1.10.1 [28]; the workflow was the same as described for the 
miRNA differential expression analysis. No outliers were found based on the 
PCA of the DESeq-normalized count data. The nbinomTest function was run for 
eleven control samples and twelve HD samples to assess differentially 
expressed genes. Multiple comparison adjustment for multiple testing with the 
Benjamini-Hochberg correction was used to control for false discovery rate. For 
Hox gene differential expression analysis, 55 comparisons were used. Genes 
located within HOX-gene containing regions were queried through the Ensembl 
database (release 72), interfacing through the R package BiomaRt [78,79]. 
Genes that were between HOXA1-HOXA13, HOXB1-HOXB13, HOXC4-HOXC13 
and HOXD1-HOXD13 start sites were regarded as “Hox genes.” For miRNA 
target differential expression, 154 comparisons were used for Benjamini-
Hochberg correction. 
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miRNA-mRNA target analysis. Information on experimentally validated 
miRNA targets of miR-10b-5p, miR-196a-5p and miR-615-3p were extracted 
from the miRWalk “Validated Targets” module [30]. Strand specificity was 
preserved. Targets for miR-196a-1 and miR-196a-2 were merged for analysis. 
IPA Core Analysis (analysis.ingenuity.com) was run as nervous system and CNS 
cell line specific across all species, using target gene lists imported from 
miRWalk output. “Bio Functions” and “Canonical Pathway” analyses were used. 
Right-tailed Fisher’s Exact Tests were run through IPA software and p-values 
with FDR-adjusted q-values (p<0.05) were considered significant. Biological 
functions across the 3 significant miRNA were compared using the IPA Core 
Comparison Analysis tool. Benjamini-Hochberg Multiple Testing Correction p-
values (p<0.05) were considered significant. 
Linear modeling of miRNA relationship to clinical covariates. To 
account for the non-normality in the miRNA data, negative binominal general 
linear regressions were performed using Proc genmod in SAS. DESeq 
normalized counts were rounded to the nearest integer before running the model. 
To test the normality of gene expression data, Shapiro-Wilk tests were 
performed. Differentially expressed miRNA data trended as non-normally 
distributed in HD (miR-10b-5p, p=0.04; miR-196a-5p, p=0.05; miR-615-3p, 
p=0.06), but not in controls (miR-10b-5p, p=0.71; miR-196a-5p and miR-615-3p 
were essential zero).  
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Generation of transgenic cell lines. PC12 (rat adrenal gland 
phaeochromocytoma) cells were grown at 37°C and 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM; Life Technologies, Carlsbad, CA) with 20% 
fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, GA), 100 units/ml 
penicillin and 100 units/ml streptomycin (Life Technologies, Carlsbad, CA). 
pcDNA3.1mycC expressing human huntingtin fragment (1-90) containing 73 
polyglutamine repeats (Coriell Institute; CHDI-90000034) was used for stable 
transfection.  Cells were seeded to 70% confluency and grown overnight. 15 µl of 
Attractene Transfection Reagent (Qiagen, Gaithersburg, MD) was added to 4 µg 
plasmid DNA diluted in 300 µl Opti-MEM (Life Technologies, Carlsbad, CA). Cells 
were grown in complete media and selected for four weeks using 500 mg/ml 
G418 (Life Technologies, Carlsbad, CA).  To create monoclonal cultures, single 
colonies were isolated using dilution cloning, picked with filter paper, grown in a 
6-well plate and screened for transgenic expression by Western blot analysis 
using mouse Anti- c-Myc (Novex, R950-25, Life Technologies, Carlsbad, CA). 
Cell differentiation and miRNA overexpression. 96-well culture plates 
were seeded with 10,000 cells per well. For differentiation, culture medium was 
replaced with medium composed of DMEM with 0.5% FBS, 100 mg/ml G418, 
100 units/ml penicillin and 100 units/ml streptomycin and 100 ng/ml nerve growth 
factor (R&D Systems, Minneapolis, MN). After 48 hr, miRNA was transfected into 
HD cells using 0.25 ul Lipofectamine 2000 (Life Technologies, Carlsbad, CA) and 
6.25 pmol miR-10b-5p or miRIDIAN microRNA Mimic Negative Control #1 (cel-
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miR-67-3p, Thermo Scientific, Waltham, MA) per well, following manufacturer’s 
protocol. miR-10b-5p overexpression was verified using qPCR. 
Cell viability assays. For MTT assays, 1 uM MG 132 (Tocris Bioscience, 
United Kingdom) was added to select wells containing 10,000 cells per well at 72 
hr post-differentiation. Cell viability was assessed at 96 hr post-differentiation. 
Following manufacturer’s protocol, CellTiter 96 Non-Radioactive Cell Proliferation 
Assay kit (Promega; Madison, WI) was used to determine cell number. Cells 
were incubated for 1.5 hr at 37°C and 5% CO2 with MTT dye solution. 
Undifferentiated HD cells were serially diluted across a 96-well plate to create a 
standard curve for cell number calculation. Absorbance was measured using Bio-
Tek Synergy H1 spectrophotometer at 540 nm for miR-10b-5p transfected wells, 
with MG 132 (n=44) and without MG 132 (n=35) and cel-miR-67-3p transfected 
wells with MG 132 (n=40) and without MG 132 (n=40). One-way ANOVA way 
used for statistical analysis. For cell viability staining, miR-10b-5p and negative 
control mimic were transfected after 48 hours of differentiation in 12-well culture 
plate with 4 replicates each, 250,000 cells per well. Molecular Probes Neurite 
Outgrowth Staining Kit (Life Technologies, Carlsbad, CA) was used according to 
manufacturer’s protocol. Using Bio-Tek Synergy H1 microplate reader, 
fluorescent area scans were taken at 530 nm excitation/590 nm emission with a 
5x5 matrix per well. 
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CHAPTER 3: MIR-10B-5P EXPRESSION IN HUNTINGTON’S DISEASE BRAIN 
RELATES TO AGE OF ONSET AND THE EXTENT OF STRIATAL 
INVOLVEMENT 
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MacDonald ME, Chen JF, Akbarian S, Weng Z, Vonsattel JP, Myers RH. miR-
10b-5p expression in Huntington's disease brain relates to age of onset and the 
extent of striatal involvement. BMC Med Genomics. 2015 Mar 1;8:10. doi: 
10.1186/s12920-015-0083-3. 	
Abstract 
Background. MicroRNAs (miRNAs) are small non-coding RNAs that recognize 
sites of complementarity of target messenger RNAs, resulting in transcriptional 
regulation and translational repression of target genes. In Huntington’s disease 
(HD), a neurodegenerative disease caused by a trinucleotide repeat expansion, 
miRNA dysregulation has been reported, which may impact gene expression and 
modify the progression and severity of HD. 
Methods. We performed next-generation miRNA sequence analysis in prefrontal 
cortex (Brodmann Area 9) from 26 HD, 2 HD gene positive, and 36 control 
brains. Neuropathological information was available for all HD brains, including 
age at disease onset, CAG-repeat size, Vonsattel grade, and Hadzi-Vonsattel 
striatal and cortical scores, a continuous measure of the extent of 
neurodegeneration. Linear models were performed to examine the relationship of 
miRNA expression to these clinical features, and messenger RNA targets of 
associated miRNAs were tested for gene ontology term enrichment. 
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Results. We identified 75 miRNAs differentially expressed in HD brain (FDR q-
value <0.05). Among the HD brains, nine miRNAs were significantly associated 
with Vonsattel grade of neuropathological involvement and three of these, miR-
10b-5p, miR-10b-3p, and miR-302a-3p, significantly related to the Hadzi-
Vonsattel striatal score (a continuous measure of striatal involvement) after 
adjustment for CAG length. Five miRNAs (miR-10b-5p, miR-196a-5p, miR-196b-
5p, miR-10b-3p, and miR-106a-5p) were identified as having a significant 
relationship to CAG length-adjusted age of onset including miR-10b-5p, the 
mostly strongly over-expressed miRNA in HD cases. Although prefrontal cortex 
was the source of tissue profiled in these studies, the relationship of miR-10b-5p 
expression to striatal involvement in the disease was independent of cortical 
involvement. Correlation of miRNAs to the clinical features clustered by direction 
of effect and the gene targets of the observed miRNAs showed association to 
processes relating to nervous system development and transcriptional regulation. 
Conclusions. These results demonstrate that miRNA expression in cortical BA9 
provides insight into striatal involvement and support a role for these miRNAs, 
particularly miR-10b-5p, in HD pathogenicity. The miRNAs identified in our 
studies of postmortem brain tissue may be detectable in peripheral fluids and 
thus warrant consideration as accessible biomarkers for disease stage, rate of 
progression, and other important clinical characteristics of HD. 
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Keywords. Huntington’s disease, Human, Prefrontal cortex, Striatum, miRNA-
sequencing, microRNA, miRNA, RNA biology, Age at onset, Neuropathological 
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Background 
Huntington’s disease (HD) is an inherited disorder caused by a CAG trinucleotide 
repeat expansion in HTT which leads to progressive motor and cognitive 
impairment due to the gradual loss of neurons within striatal and cortical brain 
regions [1]. Although monogenic, HD displays remarkable variation in clinical 
expression, most readily observed by the range in age at clinical onset as 
determined by the manifestation of motor symptoms, varying from age 4 years to 
age 80 [2]. While onset age is unequivocally related to the size of the expanded 
CAG repeat, with longer repeats leading to earlier onset, only 50% to 70% of the 
variation can be attributed to repeat size [3,4]. The remaining variation is highly 
heritable (h2 = 0.56), suggesting a strong role for genes that modify disease 
progression [3]. 
MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate 
the expression of genes in a sequence-specific manner, binding to the 3′-
untranslated region (3′UTR) to initiate cleavage or translational repression of 
target transcripts [5,6]. miRNAs influence a diverse range of cellular processes 
[7] and consequently, their altered expression may lead to or influence disease-
related pathological phenotypes, or reveal unknown aspects of the disease 
process. In the central nervous system (CNS), miRNAs are abundant, as brain-
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specific miRNAs assist in various neuronal processes such as synaptic 
development, maturation and plasticity [8,9]. Altered miRNA expression has been 
observed in diseases of the CNS, particularly in age-dependent 
neurodegenerative diseases, which suggests that the expression of miRNAs may 
contribute to neuropathogenesis [10,11]. 
In HD, the dysregulation of miRNAs has been reported in HD in vitro 
models, transgenic HD animals and human HD brain [12-24]. We hypothesize 
that post-transcriptional regulation by miRNAs plays a role in modifying the 
progression and severity of HD. Recently, we completed a study of miRNA 
expression obtained through next-generation sequencing technology in human 
HD and control brain samples to investigate the presence of altered miRNA 
expression in HD and its role in transcriptional dysregulation [13]. The original 
study provided sample power to detect large miRNA changes, but the sample 
size was not sufficient to detect more subtle changes in miRNA expression and 
did not represent a wide enough range of HD pathology to investigate 
relationships to clinical features of HD. Therefore, to follow-up on these findings, 
we have sequenced small RNAs in an additional 16 HD brains, two of which are 
gene positive asymptomatic Vonsattel grade 0 cases, and 27 control samples, for 
a combined study of 28 HD and 36 control samples. The increased sample size 
enables the detection of significantly altered miRNAs with lower levels of 
differential expression as well as more comprehensive characterization of the 
relationship of these miRNAs to relevant clinical features of the disease, 
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including the age at motor onset of the disease, disease duration (the time 
between onset and death), age at death and extent of pathological involvement 
in the striatum and cerebral cortex. A deeper understanding of the global miRNA 
expression in HD may elucidate pathogenic mechanisms of disease progression 
in HD and suggest new therapeutic targets. 
Results 
Differential expression analysis highlights disrupted miRNA 
expression in HD brain. To evaluate the relationship of miRNA expression to 
salient clinical and pathological features of HD, we profiled miRNA expression 
using small RNA-sequencing of prefrontal cortex (Brodmann Area 9) of 26 
symptomatic HD and 36 control samples (see Table 6). Although the striatum is 
the most affected brain region in HD, differences in miRNA expression between 
HD and unaffected controls, independent of cellular composition, would be 
difficult to assess due to the extent of neuron loss and the increase of reactive 
astrocytosis in HD striatal tissue [25]. Therefore, prefrontal cortex, which exhibits 
hallmark characteristics of HD pathology [26], relates to striatal involvement 
(Pearson r = 0.44, p < 2e-16) [27], but experiences less extreme changes than 
the striatum [28,29], was used for sequencing. In addition, previous studies have 
found no difference in cell counts between HD and controls from similar BA9 
brain samples [13,30]. 
The HD samples consisted of Grade 2 (n = 4), Grade 3 (n = 15), and 
Grade 4 (n = 7) brains as determined by Vonsattel grade, an assessment of 
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striatal involvement classified as 0 through 4 in order of the severity of 
neuropathological involvement [25]. Sequenced samples were also among the 
523 HD brains characterized by the recently established measure of pathological 
involvement termed the Hadzi-Vonsattel score (H-V score), which independently 
characterizes both striatal and cortical pathological involvement in each brain 
[28]. While Vonsattel grading and H-V striatal score are closely related, (Pearson 
r = 0.90, measured using 346 HD brains), H-V scores are a continuous metric 
and therefore more amenable to adjustment of covariates such as CAG repeat 
size in modeling of neuropathological involvement and independently assesses 
striatal and cortical involvement. H-V scores ranged from 0–4, where 0 indicates 
no detectable neuropathological involvement and 4 indicates severe 
neuropathological involvement. Samples from symptomatic individuals had 
striatal scores ranging 1.43–3.82 and cortical scores ranging from 0.40–2.36 
(see Table 6). Additionally, two Grade 0 brains (both with CAG repeat 
expansions of 42 repeats) were small-RNA sequenced and analyzed separately 
from the 26 HD brains used in differential expression analysis. Grade 0 brains 
were neuropathologically normal and asymptomatic at the time of death (see 
Table 1). 
 
Table 6. Summary of the brain samples used for miRNA-sequence analysis. 		
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After processing sequencing data to remove sequencing artifacts, 
normalize using variance stabilization transformation, and adjust for batch effects 
(see Methods), 938 miRNAs were reliably quantified and 75 of these were 
significantly differentially expressed in HD versus control brains after adjusting for 
multiple comparisons (FDR q-value < 0.05, see Appendix Table 1). In HD, 46 
miRNAs were identified as significantly up-regulated and 29 as down-regulated in 
their expression. Hox-related miRNAs had the most extreme, positive fold 
changes, where miR-10b-5p was 3.9 log2 fold increased, miR-196a-5p was 2.4 
log2 fold increased, miR-615-3p was 1.6 log2 fold increased, miR-10b-3p was 
1.5 log2 fold increased, and miR-196b-5p was 1.3 log2 fold increased (see 
Figure 9, see Table 7). Both the 5′ and 3′ mature miRNAs were differentially 
expressed for eight miRNA precursors (miR-10b, miR-129, miR-1298, miR-142, 
miR-144, miR-148a, miR-302a, and miR-486). In HD and controls, most 5′-3′ 
miRNA pairs were positively correlated in their expression, with the exception of 
miR-1298 in HD and miR-10b and miR-302a in controls. 
Variable HD, Grades 2 - 4 Asymptomatic Grade 0 Control
N 26 2 36
Age at death 59.5 ± 10.7 67.5 ± 26.1 68.6 ± 14.3
RNA integrity number 7.3 ± 0.9 7.7 ± 0.6 7.7 ± 0.7
Post mortem interval 15.7 ± 7.7 28.0 ± 7.9 14.4 ± 8.8
CAG repeat size 44.6 ± 2.9 42.0 ± 0
Age of onset 44.5 ± 11.8
Disease duration 15.0 ± 6.1
Striatal score 2.70 ± 0.65
Cortical score 1.25 ± 0.50
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Appendix Table 1. Differentially expressed miRNAs in Huntington’s disease 
prefrontal cortex 
 
Figure 9. Characterization of miRNA in Huntington's disease brain. 
Volcano plot of 75 significantly differentially expressed miRNA after FDR-
adjustment for 938 comparisons. Points labeled red were up-regulated in HD and 
points labeled as blue were down-regulated in HD. Hox-related miRNA points are 
labeled and represent the top differentially expressed miRNA in HD. 
 
To confirm our previously published findings, we re-analyzed the twelve HD and 
nine controls samples from our original study using our updated sequence 
analysis pipeline (see Methods) and then used the newly sequenced samples, 
consisting of 14 HD and 27 control brains, as a replication set. Fourteen miRNAs 
were significantly differentially expressed (FDR q-value < 0.05) in the original set 
using the updated analysis pipeline, compared to five differentially expressed 
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miRNA in the original study. Fourteen differentially expressed miRNAs were 
significantly differentially expressed in the replication set and thirteen of these 
fourteen were significant in the combined sequence analysis. As previously 
reported, Hox-related miRNA, including miR-10b-5p, were among the most 
strongly differentially expressed across all three studies (see Appendix Table 1). 
Firefly Bioworks microRNA assay, a multiplexed, particle-based technology using 
flow cytometry to measure miRNA levels, was used to quantify and orthogonally 
validate miRNA differential expression from sequencing (see Methods). A subset 
of 21 controls and 15 HD samples from the sequencing study were selected for 
the assay. Sixteen miRNAs with moderately high expression levels were selected 
for testing and an additional six miRNAs were used as input normalizers. miR-
10b-5p was confirmed as significant after correcting for multiple corrections (p-
value = 3.0e-10, q-value = 6.6e-9). Seven out of sixteen miRNAs assayed 
approached but did not reach significance after adjustment in this subset 
(unadjusted p-value < 0.05, miR-10b-5p, miR-194-5p, miR-223-3p, miR-132-3p, 
miR-144-5p, miR-148a-3p, miR-486-5p). Eight of the remaining nine miRNAs 
that failed to achieve significance had the same direction of effect. These results 
were consistent with the reduced power available from this subset. 
Nine miRNAs relate to Vonsattel grade. To explore the relationship of 
miRNA expression to principal clinical aspects of the disease, we next modeled 
the expression of the 75 differentially expressed miRNAs to the Vonsattel grade 
of neuropathological involvement. Analysis of variance (ANOVA) was performed 
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to compare the expression of the 75 differentially expressed miRNAs across 
Vonsattel grade in all 28 (Grade 0–4) HD gene-positive and control brains. 65 
miRNA were found to be significant in the ANOVA (FDR-adjusted q-value < 
0.05), indicating differential expression may be driven by the difference of 
controls to specific grades. Next, ANOVA was performed exclusively in HD 
brains to find whether miRNA differences exist across Vonsattel grades. Nine 
miRNAs were significant in both ANOVA tests after adjusting for multiple 
comparisons, indicating a significant difference in the expression of these 
miRNAs across Vonsattel grades (both FDR q-values < 0.05). Last, pairwise 
comparisons of each grade with the control group were performed using post-hoc 
Tukey’s HSD (honestly significant different) tests to find specific groups that 
significantly differed from one another. Figure 10 highlights the nine miRNAs that 
are associated with grade in order of statistical significance from the ANOVA 
inclusive of control brains in the test. In Figure 10, significant differences across 
grade and control groups as determined by Tukey HSD are denoted by letters (a-
d) in the grey banner above each boxplot, whereby groups with different letters 
are significantly different from one another while those which share letters are 
not. 
Figure 10. Nine miRNAs are associated with Vonsattel grade. 
In HD brains, expression of differentially expressed miRNA was compared 
across Vonsattel grades 0–4. Boxplots represent nine FDR-significant miRNAs 
(FDR q < 0.05, adjusted for 75 contrasts) associated with Vonsattel grade by 
analysis of variance (ANOVA). X-axes represent Vonsattel grade, classified 0–4 
in order of the severity of striatal involvement and Y-axes show the VST 
expression values after batch correction. Significant differences across grades 
and controls are denoted by letters in the grey banner above the boxplot, labeled 
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a-d. Groups with different letters are significantly different from one another while 
those with the same letter are not, after correcting for multiple comparisons. For 
example, group “a” would be significantly different from group “b” and “c.” 
Conditions represented by multiple letters indicate no significant difference 
among those groups. For example, group “ab” would not be significantly different 
than groups “a” and “b,” but would be different group “c.” A. miR-10b-5p. B. miR-
196a-5p. C. miR-10b-3p. D. miR-196b-5p. E. miR-302a-3p. F. miR-200c-3p. G. 
miR-4488. H. miR-4449. I. miR-663b. 	
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Several patterns in the relationship of grade to miRNA expression were 
observed. First, the expression of miR-10b-5p was significant in nearly all 
comparisons; pairwise contrasts between all grades as well as with the control 
group were different except for grade 0, although grade 0 was different than 
grades 2, 3 and 4 (see Figure 10A). Second, the expression of miRNAs in grade 
0 brains was rarely different than controls, with the exception of miR-200c-3p, 
where its expression in grade 0 brains was significantly lower than both controls 
and grades 2–4 brains (see Figure 10G). Third, the expression of miRNAs in 
grade 3 and 4 brains appeared relatively similar to one another, with the 
exception of miR-10b-5p, as mentioned above, and miR-4488, where grade 3 
brains were significantly lower than all other groups (see Figure 10D). Although 
not significant in the HD-only ANOVA, significant pairwise differences between 
grade 3 and 4 were observed for miR-1298-5p (Bonferroni q-value = 3.6e-2) and 
miR-615-3p (Bonferroni q -value = 2.2e-2). 
To assess the sensitivity and specificity of miR-10b-5p for predicting HD, 
area under the curve (AUC) values were calculated using receiver operating 
characteristic curves (ROC). When comparing HD to controls to predict HD, the 
AUC was 99.47% (95% confidence level was 98.46%-100%). In a comparison of 
asymptomatic HD to HD to predict HD status, the AUC was 98.08% (95% 
confidence level was 92.75-100%) and comparing asymptomatic HD to controls, 
the AUC was 84.72% (95% CI: 71.09%-98.36%). 
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miRNA expression relates to striatal involvement and age of onset in 
HD. To further elucidate the meaning of the associations of the miRNAs to HD, 
we examined the relationship between the 75 differentially expressed miRNAs 
and other salient features of the disease (age at motor onset, disease duration, 
age at death, and H-V scores of striatal and cortical involvement). To avoid 
confounding the analysis of these clinical features by the known, strong 
relationship between HTT CAG repeat size and disease pathology and onset 
[4,28,31,32], CAG-adjusted residuals were calculated for all continuous clinical 
traits (see Figure 11). 
Figure 11. Association of clinical features to HD CAG repeat size. 
CAG-adjusted residuals for onset age, death age, duration, H-V striatal score 
and H-V cortical score were computed from data derived from 346 HD brain 
samples with CAG repeat sizes <56 from Hadzi et al. [28]. Red dots represent 
samples studied in these analyses. 
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Using linear regression analysis and applying FDR-adjustment for the 75 
comparisons, three miRNAs (miR-10b-5p, miR-10b-3p, miR-302a-3p) were 
observed to have a significant relationship to CAG-adjusted striatal score (FDR 
q-values = 2.28e-2). All three were significant in the analysis of miRNA 
expression to Vonsattel grade (see above). Additionally, five miRNAs were 
identified as having significant association to CAG-adjusted age of onset (miR-
10b-5p, FDR q-value = 3.49e-3; miR-196a-5p, FDR q-value = 1.32e-2; miR-
196b-5p, FDR q-value = 1.71e-2; miR-10b-3p, FDR q-value = 1.71e-2; miR-
106a-5p, FDR q-value = 1.71e-2). Figure 12 highlights the relationship of miR-
10b to CAG-adjusted striatal score and onset, where both 3p and 5p mature 
sequences of miR-10b were the only miRNA species to have significant, linear 
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association to these two clinical features independent of CAG effect. No FDR-
significant relationships of miRNA to disease duration or death age were 
observed. 
 
Figure 12. miR-10b is associated with age of onset and striatal involvement. 
In 26 Vonsattel grade 2, 3 and 4 HD brains, both mature miR-10b sequences (-
5p and -3p) have FDR-significant relationships to clinical features of HD. Y-axes 
show the variance stabilizing transformation expression values after batch 
correction. Grade 0 cases are not included, as they have neither onset age nor 
Hadzi-Vonsattel (H-V) striatal score. A. Scatterplot of miR-10b-5p expression and 
CAG-adjusted H-V striatal score. B. Scatterplot of miR-10b-3p expression and 
CAG-adjusted H-V striatal score. C. Scatterplot of miR-10b-5p expression and 
CAG-adjusted onset age. D. Scatterplot of miR-10b-3p expression and CAG-
adjusted onset age. 
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No significant relationship of the expression of the 75 differentially 
expressed miRNA to CAG-adjusted cortical score was observed, although 
nominal associations were seen. In order to account for the potential impact of 
cortical involvement on the relationship of miRNA expression to striatal 
involvement, we performed a multivariate regression analysis modeling miRNA 
expression to striatal H-V score while correcting for cortical H-V score. After 
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CAG-adjusted cortical score correction, CAG-adjusted striatal score remained 
significant (miR-10b-5p p-value = 0.04, miR-10b-3p p-value = 0.01, miR-302a-3p 
p-value = 0.005). 
Last, to characterize the patterns of association of miRNAs to clinical 
features, Pearson coefficients of the correlation of the expression of the 
differentially expressed miRNAs to five CAG-adjusted features (onset age, 
disease duration, death age, striatal score and cortical score) were hierarchically 
clustered. Grade 0 and controls samples were not included in these analyses. 
Correlation coefficients rather than beta coefficients were used in order to 
standardize the direction of effect. Here, we observed differentially expressed 
miRNAs with correlation p-values < 0.05 clustered into distinguishable patterns of 
association to clinical variables (see Figure 13). Differentially expressed miRNAs 
increased in HD compared to controls tended to have negative correlations with 
onset and death, and positive correlations with striatal and cortical score. 
Conversely, differentially expressed miRNAs with negative relative fold changes 
had positive correlations with onset and death, and negative correlations with 
striatal and cortical scores. 
Figure 13. CAG-adjusted clinical features of HD show patterns of 
association with miRNA expression. 
CAG-adjusted measures of onset age, disease duration, death age, Hadzi-
Vonsattel (H-V) striatal and cortical score were correlated with differentially 
expressed miRNAs in HD brains. miRNAs with at least one nominal p-value < 
0.05 are shown. Pearson correlation coefficients and features were 
independently hierarchically clustered. Red boxes indicate positive correlations 
and blue boxes indicate negative correlations. Seven miRNAs in the left section 
are down-regulated in HD and the ten miRNAs in the right section are up-
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regulated. Unsupervised clustering separated miRNA by their direction of fold 
change. 	
 
Targets of HD-related miRNAs are associated with nervous system 
development and transcriptional regulation. To attempt to understand the 
potential functional impact of miRNA dysregulation in HD, gene ontology 
enrichment was performed using predicted targets for miRNAs that correlated 
with clinical features and were suitably annotated in Targetscan (twelve miRNAs 
in total). 5712 unique mRNA targets for miRNAs with positive fold change in HD 
(miR-106a/302a-5p, miR-196a/miR-196b, miR-302a-3p, miR-363, miR-10b, miR-
615-3p), and 6572 mRNA targets for negative fold change in HD (miR-129-3p, 
miR-129-5p, miR-132-3p, miR-4449, miR-4488, miR-490-5p) were found using 
Targetscan [33], and stratified by fold change for gene ontology term (GO) 
enrichment analysis. Using TopGO’s weight algorithm with Fisher’s Exact Test 
for gene ontology term enrichment and a weighted p-value cutoff less than p < 
0.05, 354 GO Biological Processes, 86 GO Molecular Functions and 62 GO 
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Cellular Component terms for mRNA targets of down-regulated miRNA were 
significant. 260 GO Biological Processes, 78 GO Molecular Functions, 48 GO 
Cellular Component terms for mRNA targets of up-regulated miRNA were 
significant. 
To make these long lists of GO terms more intelligible, terms were 
summarized using semantic similarity measures to remove gene-set and GO 
term redundancy (see Methods). 
Targets of up- and down-regulated miRNAs had substantial overlap in 
their overall function. Three of the top twenty collapsed GO Biological Processes 
terms were shared between the two sets of targets (see Figure 14A). These 
terms were “nervous system development,” “Fc-epsilon receptor signaling 
pathway,” and “proteasome − mediated ubiquitin − dependent protein catabolic 
process.” “Nervous system development” was the most significant term in both 
sets (Up p = 8.5e-5, Down p = 9.9e-7). The top enriched term was “positive 
regulation of transcription, DNA-templated”, (N = 1678, p = 2.7e-4) for the 
positive gene set and “synaptic transmission”, (N = 3166, p = 3.4e-6) for the 
negative gene set. Of the 78 up-regulated Molecular Function terms and 86 
down-regulated terms, fifteen terms were the same (see Figure 14B). Top terms 
were included “sequence-specific DNA binding transcription factory activity”, 
“sequence-specific DNA binding” and “calcium ion binding”. Though shared 
between the two groups, “transcription factor binding” was enriched higher in 
down-regulated miRNAs than positive ones. For GO Cellular Component, six 
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terms were the same between the two gene sets. These terms included 
“nucleus” and “cytoplasm” as well as “cell junction” (see Figure 14C). 
Figure 14. Gene ontology terms are similar for mRNA targets of clinically 
relevant deregulated miRNAs. 
Figure 14A illustrates the overlap in GO Biological Processes between targets of 
increased miRNA (in orange) and decreased miRNA (in blue) in HD. The x-axis 
shows the number of gene ontology terms that fall within a given semantic term 
set, and the y-axis lists the top twenty enriched terms for each set of miRNA 
targets. Darker colored points represent terms with higher significance and the 
size of the points represents the union of all genes that fall within a given the 
term. A number of terms, including “nervous system development” as well as 
terms relating to transcriptional regulation are shared across up- and down-
regulated miRNA target groups. The similarity targets of up-regulated miRNA (in 
orange) and down-regulated miRNA (in blue) for GO Molecular Function are 
seen in Figure 14B and for GO Cellular Component in Figure 14C. 
 
Discussion 
In a next-generation sequence analysis of small non-coding RNAs in 26 
HD and 36 control brains we detected 938 miRNAs and 75 of these were 
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differentially expressed. All five miRNAs reported as differentially expressed in 
our previous study (miR-10b-5p, miR-196a-5p, miR-196b-5p, miR-615-3p and 
miR-1247-5p) were significantly differentially expressed in this study [13]. These 
results were independently validated in the 41 (14 HD and 27 control brains) 
newly studied brains (see Appendix Table 1), and support the presence and 
robust up-regulation of Hox-related miRNAs in HD brain [13]. The increased 
number of differentially expressed miRNAs is likely due to an increase in sample 
size. Increasing our sample size (from N = 21 to N = 62) enhanced the statistical 
power to detect additional miRNAs with smaller but significant changes in miRNA 
expression. We believe these miRNA signals are not attributed to a change in 
BA9 architecture, influenced by neuronal cell death or reactive glial response, 
because cell numbers between HD and controls from the same brain samples 
were indistinguishable [13,30]. 
Dysregulation of several miRNAs from our study have been observed in 
HD in other contexts. Concordant with our findings, miR-132-3p down-regulation 
in human HD parietal cortical tissue [15] and in brains of R6/2 and YAC128 HD 
mouse models has been observed [15,18]. miR-132 is highly enriched in the 
brain [34,35] and its expression has been shown to affect neuron morphogenesis 
and enhance neurite outgrowth by suppressing the GTPase-activating protein 
p250GAP (p250GAP/RICS) [36]. Another target of miR-132 is 
acetylcholinesterase (ACHE), which encodes an enzyme responsible for the 
breakdown of the neurotransmitter acetylcholine at the neural synapse [37]. 
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Acetylcholinesterase is critically involved in cognition, and acetylcholinesterase 
inhibitors are FDA-approved for the treatment of cognitive impairments in 
Alzheimer’s disease [37]. Thus, decreased miR-132 levels may negatively impact 
brain health, through the dysregulation of p250GAP (limiting its suppression) and 
ACHE (indirectly decreasing acetylcholine levels). 
Differentially expressed miRNAs may also target HTT transcripts as a 
response to mutant HTT to reduce HTT transcriptional levels and limit toxicity. 
miRNAs that target the HTT 3′UTR and reduce HTT transcript levels in vitro, 
miR-148a-5p, miR-150-5p and miR-214-5p, were significantly up-regulated in 
their expression [21,38]. Although miR-196a does not directly target HTT [33], 
increased miR-196a expression was observed in a primate model of HD and its 
over-expression in vitro and in animal transgenic models suppressed mutant HTT 
expression [24]. The miRNAs with the largest effect in our study, miR-10b-5p, 
putatively targets HTT by binding to two 3′UTR sites (both 7mer-1A seed, 
positions 2742–2748 and 3301–3307) and may reduce expression of HTT 
although it is not clear whether or not this would be neuroprotective [33]. 
However, miR-10b-5p also targets brain-derived neurotrophic factor (BDNF) [39], 
a growth factor required for the survival and differentiation of striatal neurons 
[40]. BDNF has been extensively studied in HD [41], as normal huntingtin protein 
is reported to up-regulate BDNF levels, while mutant huntingtin impairs BDNF 
protein abundance which may consequently lead to death of striatal neurons [42]. 
Because of the potential biological importance of BDNF, and the possibility that 
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miR-10b-5p may diminish translation of BDNF, over-expression of miR-10b-5p 
might be harmful to neuronal cells. However, in Hoss et al. [13], we showed that 
ectopic expression of miR-10b-5p in PC12 cells expressing a mutant huntingtin 
fragment enhanced cell survival [13], and miR-10b-5p has been observed to 
facilitate neurodifferentiation [43]. Given its high levels of differential expression, 
strong relationship to striatal involvement and age at onset, more research into 
miR-10b-5p is justified to understand its role in the pathogenesis of HD, its 
potential as a biomarker of disease progression and its potential as a therapeutic 
target. 
The cell type most responsible for miRNA changes cannot be determined 
from these data. Tissue homogenate was used for sequencing, so the source of 
miRNA signal is likely both neuronally and non-neuronally derived. To determine 
the miRNA cellular specificity in the brain, Jovicic et al. [16] measured miRNA 
expression in cultured neurons, oligodendrocytes, microglia and astrocytes to 
find miRNAs enriched for each cell type. Based upon this study, miRNAs found 
to be specifically enriched in neuronal cultures (miR-129-3p, miR-129-5p, miR-
132, miR-135b, miR-431, miR-433) were all down-regulated in our study whereas 
miRNAs enriched in microglial cultures (miR-126-5p, miR-126-3p, miR-141, miR-
142-3p, miR-142-5p, miR-150, miR-200c and miR-223) were all were up-
regulated. According to these enrichment categories, microglial activation 
miRNAs do not relate to clinical features of the disease. Conversely, three 
neuronal-related miRNAs, miR-129-3p/5p and miR-132, were associated with 
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pathological involvement (see Figure 13). Therefore, we hypothesize that 
differential expression of those miRNAs related to neuron function may also 
relate to the HD pathology. 
The relationship of the expression of miRNAs with Vonsattel grade 
suggests expression changes may occur early in the disease process (see 
Figure 10). Many of these miRNA changes appear present ordinal trends with an 
increase (miR-10b-5p, miR-10b-3p, miR-302a, miR-196a-5p, miR-196b-5p) or 
decrease (miR-663b, miR-4488, miR-4449) in their expression across grade. In 
particular, miR-10b-5p was significantly different across all groups, with the 
exception of the asymptomatic grade 0 brains and we believe this is an issue of 
statistical power. It is possible that the expression of these miRNAs may relate to 
HTT aggregation or proteasomal degradation, as intranuclear inclusions are 
observed in pre-symptomatic HD [44] and the density of aggregate formation 
continues over the course of the disease. Three miRNAs (miR-10b-3p/5p, miR-
302a) related to H-V striatal score, independent of the CAG repeat expansion 
size and for miR-10b-5p, independent of cortical involvement. These results 
suggest the relationship of miRNA expression to striatal involvement in the 
disease is independent of cortical involvement, which is a critical finding, 
because prefrontal cortex was the source of tissue profiled in these studies. 
Based on correlation (see Figure 13), up-regulated miRNAs clustered 
together based on their relationships to clinical features. Generally, these 
miRNAs had strong, positive associations to striatal and cortical H-V scores, 
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weak positive association with disease duration and strong negative associations 
to onset and death age. Down-regulated miRNAs clustered together as well but 
were less defined in their relationships to clinical features. Most down-regulated 
miRNAs were inversely associated with H-V scores and duration, opposite to up-
regulated miRNAs. These patterns suggest that decreasing up-regulated 
miRNAs and increasing down-regulated miRNA may be beneficial. However, it 
remains to be determined which altered miRNAs are compensatory and 
potentially neuroprotective and which are pathological and neurotoxic. 
Furthermore, it is unknown whether these changes are consequential, revealing 
important molecular aspects of the disease process, or are simply innocent by-
products. 
However, using target analysis and GO term enrichment, we observed 
predicted targets of both up- and down-regulated miRNAs shared many of the 
same biological processes and overall systems relating to “nervous system 
development.” Both sets contained several transcriptional regulation related 
terms (transcriptional regulation, DNA-dependent or RNA polymerase II, 
chromatin remodeling, post-transcriptional gene regulation, chromatin 
remodeling, etc.). Both sets of genes contained terms on metabolism, apoptosis, 
metal-binding and ubiquitin. Disruption to any of these systems may affect 
neuron health. Overall, these finding imply both up- and down-regulated miRNAs 
many be part of the same or similar biological pathways. 
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Conclusions 
Our findings identify many miRNA alterations in HD brain and a large 
number of these are related to clinical manifestations of the disease, where the 
signal is independent of the size of the CAG repeat expansion. The study of 
Grade 0 cases suggests that miR-10b-5p expression changes may occur pre-
symptomatically. Up- and down-regulated miRNAs may target genes in similar 
biological systems, and these genes are involved in transcriptional regulation, 
neuronal development and other important aspects surrounding neuron function. 
These miRNAs represent attractive candidates for predicting onset age and 
overall health of the striatum in HD. Studies pursuing these miRNAs as potential 
biomarkers for HD are in progress, as miRNAs may be detectable in peripheral 
fluids [45] and thus have potential to function as accessible biomarkers for 
disease stage, rate of progression, treatment efficacy and other important clinical 
characteristics of HD. 
Methods 
Sample information. Frozen brain tissue from prefrontal cortex 
Brodmann Area 9 (BA9) was obtained from the Harvard Brain and Tissue 
Resource Center McLean Hospital, Belmont MA, Banner Sun Health Research 
Institute, Sun City, Arizona [46] and Human Brain and Spinal Fluid Resource 
Center VA, West Los Angeles Healthcare Center, Los Angeles, CA. 26 
Huntington’s disease (HD) samples, 2 asymptomatic HD gene carriers, and 36 
neurologically and neuropathologically normal control samples were selected for 
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the study. HD subjects had no evidence of other neurological disease based on 
neuropathological examination. HD samples and controls were not different in 
postmortem interval (PMI) (p-value = 0.69), RNA integrity number (p-value = 
0.08) or gender (p-value = 0.51) but differed in ages at death (HD mean age 
=59.5, control mean age =68.6; p-value = 0.01) (see Table 1). Asymptomatic HD 
samples did not differ in age at death (mean age =67.5) in comparison to HD or 
control samples (control p-value = 0.92; HD p-value = 0.40). Information on CAG 
genotype, onset age, death age, disease duration, Vonsattel grade, Hadzi-
Vonsattel striatal and cortical scores for HD samples can be found on GEO. 
Total RNA was isolated using QIAzol Lysis Reagent and purified using 
miRNeasy MinElute Cleanup columns. RNA quality for sequencing was 
assessed using Agilent’s BioAnalyzer 2100 system and RNA 6000 Nano Kits to 
determine RNA Integrity Number or Agilent 2200 TapeStation and Agilent DNA 
ScreenTape assay RNA Quality Number. For each brain sample, 1 ug of RNA 
was used to construct sequencing libraries using Illumina’s TruSeq Small RNA 
Sample Prep Kit, according to the manufacturer’s protocol, and sequenced using 
1x51nt single-end reads on Illumina’s HiSeq 2000 system at Tufts University 
(http://tucf-genomics.tufts.edu/) or the Michigan State sequencing core facility 
(http://rtsf.natsci.msu.edu/genomics/). 
miRNA sequence analysis. Reads were quality filtered, removing reads 
below 80% Q20, using FASTX-toolkit FASTQ quality filter (version 0.0.13.2, 
http://hannonlab.cshl.edu/fastx_toolkit/). Adapter sequence (5′-
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TGGAATTCTCGGGTGCCAAGG-3′) was removed from the 3′ end of all reads 
using cutadapt 1.2.1 (http://code.google.com/p/cutadapt/) and reads less than 15 
nucleotides in length were discarded [47]. Reads were collapsed using FASTX-
toolkit FASTA/Q collapser. Reads were aligned to the UCSC human reference 
genome (build hg19) using Bowtie version 1.0.0, using no mismatch alignments 
and a limit of 200 multiple mapping instances [48]. Aligned reads that overlapped 
with the human miRNA annotation, miRBase version 20, 
(http://www.mirbase.org/ftp.shtml) were identified using BEDTools IntersectBed 
[49]. Reads longer than 27 bases were removed. miRNA reads were counted if 
±4 nucleotides from the mature, annotated 5′ start coordinates. Reads that 
mapped to multiple locations, represented by a single mature miRNA, were 
recorded as a single miRNA count. Multi-mapped reads represented by multiple 
mature miRNA annotations were discarded. R version 3.1.0 and Bioconductor 
2.1.4 version were used for differential expression analysis. DESeq2 version 
1.40.0 was used for estimation of library size and correction, as well as variance-
stabilizing transformation (VST) [50,51]. miRNAs with a mean less than 2 raw 
read counts across all samples were removed. Batch effect was corrected using 
ComBat with default options through the Bioconductor package sva 3.10 [52,53]. 
All samples were included in VST and batch correction. Using 36 controls and 26 
HD grades 2–4, differential expression analysis was performed with LIMMA 
version 3.20.8 [54,55], adjusting for age at death in the model. Q-values were 
FDR-adjusted for 938 comparisons. The unprocessed fastq files, normalized 
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miRNA counts and results from miRNA differential expression analysis have 
been deposited in NCBI’s Gene Expression Omnibus [56], and are accessible 
through GEO Series accession number GSE64977 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64977). 
Firefly miRNA assay. A panel of 16 differentially expressed miRNAs with 
moderate to high expression (miR-10b-5p, miR-194-5p, miR-223-3p, miR-132-
3p, miR-144-5p, miR-148a-3p, miR-486-5p, miR-363-3p, miR-199a-5p, miR-16-
2-3p, miR-142-3p, miR-34c-5p, miR-129-5p, miR-433-3p, miR-885-5p, miR-346) 
and six stably expressed miRNAs in sequencing (miR-9-5p, miR-92a-3p, miR-98-
5p, miR-101-3p, miR-151a-3p, miR-338-3p) was used for validation. In a 96-well 
filter plate, Firefly Multimix (Firefly BioWorks, www.fireflybio.com) was incubated 
with 25ul Hybridization Buffer and 25ul total RNA at a concentration of 1 ng/ul at 
37°C for 60 minutes. After rinsing to removing unbound RNA, 75ul of Labeling 
Buffer was added to each well, and the plate was incubated for 60 minutes at 
room temperature. Adapted-modified miRNAs were released from the particles 
using 90°C water, and PCR amplified using a fluorescently-label primer set. PCR 
product was hybridized to fresh Firefly Multimix for 30 minutes at 37°C and re-
suspended in Run Buffer for readout. Particles were scanned on an EMD 
Millipore Guava 8HT flow cytometer. Raw output was background subtracted, 
normalized using the geometric mean of the six normalizer miRNAs and log-
transformed. LIMMA version 3.20.8 [54] was used to calculate significance. 
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HD feature analysis. For analysis of miRNA expression to Vonsattel 
grade, Tukey HSD statistics and compact letter display were generated by the 
multcomp R package [57]. CAG-adjusted age of onset was calculated using the 
logarithmic model from Djousse et al. 2003 [4]. Hadzi-Vonsattel striatal and 
cortical scores were measured in 523 HD brain samples as previously described 
[28]. Samples with greater than 55 repeats or missing CAG information were 
excluded from analysis, leaving 346 samples. To provide robust residual 
estimates for the subset of samples included in the sequencing project, H-V 
striatal score, H-V cortical score, death age and disease duration features were 
corrected for CAG size by modeling each feature to CAG size within the HD 
dataset (N = 346) and the residuals from the model were extracted for each 
sample (see Figure 11) [28]. VST-batch corrected counts were used for all 
subsequent analyses. CAG-adjusted residuals and miRNA expression 
relationships were analyzed using linear regressions. Covariates (PMI, RIN, age 
at death) were not included in linear models, as neither PMI nor RIN were 
determined to have an effect on the outcome of the results. Age at death could 
not be included in the analysis due to the relationship of age at death and HD 
clinical pathology. Q-values were FDR-adjusted for 75 differentially expressed 
miRNA contrasts for linear regressions were reported. 
For the cluster analysis in Figure 13, Pearson correlations for miRNA expression 
to clinical feature were performed and those miRNAs with p-values < 0.05, 
without adjustment for multiple comparisons, were reported. Pearson correlation 
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coefficients were hierarchically clustered using Euclidean distance and 
unsupervised complete clustering method through the R-package pheatmap 
version 0.7.7. 
Target prediction and gene ontology enrichment. Targetscan, release 
6.2 [33] was used to select mRNA targets of miRNAs with at least one 
relationship to clinical feature. Fourteen miRNAs were available on Targetscan 
and twelve miRNAs had unique seed sequences. Targets were removed with 
total context scores ≥ −0.1. miRNAs with positive fold change in HD (miR-
106a/302a-5p, miR-196a/miR-196b, miR-302a-3p, miR-363, miR-10b, miR-615-
3p), and negative fold change in HD (miR-129-3p, miR-129-5p, miR-132-3p, 
miR-4449, miR-4488, miR-490-5p) were stratified for gene ontology term (GO) 
enrichment analysis. GO term enrichment for “biological processes,” “molecular 
function,” and “cellular component,” was performed using topGO [58] with the 
“weight01” algorithm and Fisher statistic within the R statistical environment. A 
weighted Fisher p-value < 0.05 threshold was used to select significant GO 
enrichment. Significant terms were collapsed by semantic similarity using the 
program REVIGO [59], with p-value included for each term and using the “Small 
(0.5)” similarity setting. The union of genes from REVIGO “parent” terms was 
calculated using topGO’s genes.in.term function. 
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CHAPTER 4: STUDY OF PLASMA-DERIVED MIRNAS MIMIC DIFFERENCES 
IN HUNTINGTON’S DISEASE BRAIN 	
Citation: Hoss, A. G., Lagomarsino, V. N., Frank, S., Hadzi, T. C., Myers, R. H. 
and Latourelle, J. C. (2015), Study of plasma-derived miRNAs mimic differences 
in Huntington's disease brain. Movement Disorders. doi: 10.1002/mds.26457 
 
Introduction 
Huntington’s disease (HD) is an autosomal dominant inherited movement 
disorder, caused by an expanded CAG trinucleotide repeat sequence in the 
huntingtin gene [1].  The emergence of abnormal, choreiform movements, often 
accompanied by neurophysiological, psychiatric or cognitive impairments [2], 
defines disease onset and generally occurs around middle age [3]. 
Neurodegeneration precedes clinical diagnosis. As many as half of the neurons 
in the caudate nucleus in the striatum are lost by the onset of motor signs of 
disease [4], and volumetric changes in the striatum occur as early as two 
decades prior to predicted onset age [5]. Because motor and cognitive 
impairments correlate with the neuroanatomical changes in the striatum [6], to 
prevent neuronal loss and thereby prevent or delay disease onset, therapeutic 
intervention would ideally occur prior to HD manifestation.  
While predictive genetic testing can reliable detect HD, the lack of validated 
biomarkers for HD progression limits the evaluation of preventive and early-stage 
disease-modifying therapies. Current progressive measures for prodromal and 
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early-stage HD patients rely on rating of functional decline, which are susceptible 
to inter-rater variability and limited sensitivity [2]. 
Large, multicenter, longitudinal studies comparing large cohorts of 
asymptomatic HD gene carriers and early-stage HD to healthy controls have 
used a battery of clinical and neuroimaging based assessments, aimed at 
identifying robust quantitative measures [7, 8]. These studies, among others, 
have identified a number of image-based biomarkers that may relate to HD 
progression, such as morphometric changes [7, 9], elevation in the glial cell 
marker myo-inositol [10], the reduction in the neuronal integrity marker N-acetyl 
aspartate [10], and recently, the medium spiny neuron marker PDE10A [11]. 
Although neuroimaging biomarkers are encouraging, prior to clinical adoption, 
problems in reproducibility across imaging facilities from technical and analytical 
inconsistencies must first be addressed [12]. 
Alternatively, the disease mechanisms that are observed in the brain may 
be detectable in the blood.  Research measuring oxidative stress using 8OHdG 
levels [13], mutant HTT accumulation [14], inflammatory markers [15], and 
genome-wide RNA changes [16-18], have uncovered a number of concordant 
changes between brain and blood. While promising, the clinical utility of these 
measures is yet to be reported. 
Recently, we completed comprehensive evaluations of altered miRNA 
levels obtained through next-generation sequencing technology in human HD 
and control prefrontal cortex samples to investigate their role in transcriptional 
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dysregulation in this disease [19]. We identified 75 miRNAs significantly altered 
in HD and several of these showed significant associations to HTT CAG repeat-
adjusted age at motor onset, or extent of striatal neuropathological involvement 
[20], including miR-10b-5p, associated with both. Furthermore, among 
asymptomatic HD gene carriers, levels of miR-10b-5p were distinguishable from 
both the low expression observed in normal controls and higher levels seen 
among symptomatic HD patients, suggesting a relationship between cortical 
levels of miR-10b-5p and disease stage.  
Because brain-derived miRNAs may pass through the blood-brain-barrier 
by exosome transport [21], and because they are remarkably stable [22], the 
miRNAs identified in our studies of postmortem brain tissue may be detectable in 
peripheral fluids [23-25], and thus potentially provide accessible biomarkers for 
disease stage and rate of progression in clinical trials.  
The first step in the evaluation of clinical utility is to determine whether the 
observed HD brain-related miRNA alterations may also be detected in peripheral 
samples. To evaluate the biomarker potential for miRNAs, we compared the 
levels of four miRNAs related to HD clinical features in postmortem brains (miR-
10b-5p, miR-486-5p, miR-132-3p, and miR-363-3p) in HD, asymptomatic and 
healthy control plasma samples. 
Methods 
Study participants (n=38) were recruited through the Boston University 
Neurological Associates (BUNA) and Tewksbury State Hospital from 2012-2014, 
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with appropriate IRB approval and consent (Protocol Number H-31052) (see 
Table 7). No significant differences were observed in the age or sex distribution 
between any of the 3 groups (HD cases, asymptomatic HD carriers, and 
controls).  A trained phlebotomist drew blood by standard practice. BD 
Vacutainer CPT Mononuclear Cell Preparation Tubes containing 0.1 mL sodium 
citrate anticoagulant and 0.1 M Ficoll medium were used to isolate plasma from 8 
mL of whole blood.  
Table 7. Summary of the samples used for the study. 	
 
One mL of plasma was used for RNA extraction. To minimize platelet 
contamination [26], residual platelets were removed by centrifugation, collecting 
supernatant after spinning for 5 min at 16,000 x g. 0.22 um filtration was used to 
remove heterogeneous, phospholipid membrane bound microparticles, 0.05-1.5 
um in size, shed from platelets and other blood cells [27]. RNA was extracted 
using Qiazol and miRNeasy RNA isolation kit from Qiagen, according to 
manufacturer’s protocol. RNA purity and abundance was assessed by 
spectrophotometry.  
The four miRNAs included in this study were selected based on the 
following criteria: (1) All four were altered at genome-wide significant levels in HD 
brain [20] (up in HD: miR-10b-5p, miR-486-5p, miR-363-3p; down in HD: miR-
Condition N Age Onset age Gender 
Control 8 46.1 ± 13.5 ! 3M, 5F 
Asymptomatic 
HD 4 42.5 ± 28.7 
! 1M, 3F 
Manifest HD 26 53.0 ± 8.7 47.6 ± 9.9 11M, 15F !
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132-3p). (2) All four were readily abundant in both brain and blood [28], and (3) 
candidate miRNAs showed nominal association in the cortical study (p<0.05) to 
CAG-adjusted clinical HD features (onset: miR-10b-5p, miR-486-5p miR-363-3p; 
striatal neuropathological involvement: miR-10b-5p, miR-132-3p).  
Exiqon miRCURY LNA Universal RT miRNA PCR was used to assay miR-10b-
5p (cat. 205637), miR-486-5p (cat. 204001), miR-132-3p (cat. 204129), and miR-
363-3p (cat. 204726), following the manufacturer’s protocol. UniSp6 synthetic 
spike-in was used to evaluate cDNA efficiency. Following cDNA synthesis, 
samples were diluted to 0.2 ng/ul in RNAse free water. Both SNORD44 (cat. 
203902) and miR-451a (cat. 204737) were used for normalization. For 
quantitative PCR (qPCR), samples were assayed in triplicate across three 384-
well plates, using Applied Biosystems 7900HT Real-Time PCR System. For 
analysis, threshold cycle (CT) values for triplicate wells were normalized by 
average RNU44 and miR-451a values. Extreme outlier wells and samples 
(standard deviations above 10) were removed. miRNA levels were calculated 
using the ΔΔCT method [29].  
Linear regression analyses predicting -ΔΔCT were used to test the 
association between miRNA levels and disease status in HD cases and controls 
for the four miRNA. One-tailed tests were used to test the a priori hypothesis of 
consistent direction of effects as observed in the brain study, thus any 
relationships inconsistent with the cortical findings would not be identified as 
significant. Bonferroni correction, assuming four comparisons was applied. 
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For miR-10b-5p, we further examined the relationship between asymptomatic HD 
gene carriers and HD cases and controls separately using linear regression, 
again using a one-tailed test of the previously observed relationships. In addition, 
cumulative logit models using the “ordinal” package in R [30], were applied to test 
an ordinal relationship between controls, asymptomatic gene carriers and HD 
cases using a Chisq likelihood-ratio test. Finally, we examined the relationship of 
miR-10b-5p to age of motor onset in cases using linear regression.    
Results 
All four miRNAs were detected in plasma at reasonable levels (miR-10b-
5p average CT= 33.8, miR-132-3p average CT= 32.4, miR-363-3p average CT= 
32.2, miR-486-5p average CT= 25.7). After calculating -ΔΔCT, levels of candidate 
miRNAs in the 26 HD patients were compared to the 8 controls to test whether 
miRNAs alterations in HD plasma resembled changes in observed in HD brain. 
We observed increased levels of miR-10b-5p (one-sided p= 6.77e-3, β= 2.39) 
and miR-486-5p (one-sided p= 0.044, β= 1.44) between HD and control subjects. 
These changes are consistent with the changes observed in the brain [20] where 
miR-10b-5p and miR-486-5p were also increased (see Table 8). Levels of miR-
132-3p in plasma, though not significant, were lower in HD, consistent with the 
results in brain (one-sided p = 0.92, β= -0.62). miR-363-3p levels were not 
altered in blood, nor consistent with changes observed in HD brain (one-sided p 
= 0.99, β= -7.93e-2). 
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Table 8. Comparison of miR-10b-5p, miR-486-5p, miR-132-3p, and miR-363-
3p levels in plasma between control and HD patients. 
miR-10b-5p and miR-486-5p are significantly increased in HD blood in same 
direction as changes observed in HD brain. miR-132-5p and miR-363-3p were 
not altered in HD blood. 
 	
	
 
One of the four candidate miRNAs, miR-10b-5p, also showed significant 
association to age at motor onset and to disease stage in the brain study. 
Therefore, we focused next on miR-10b-5p and its relationship to HD 
symptomology. We did not see consistency in the relationship between miR-10b-
5p and onset age in blood (one-sided p= 0.99, positive effect) compared to that 
observed in HD brain (negative effect) although a positive association of miR-
10b-5p levels in blood to onset age, opposite to that seen in brain, may exist 
(two-sided p=3.20e-3, beta=0.13). 
  Although there was no statistical difference between asymptomatic HD 
patients and controls in miR-10b-5p levels, (one-sided p= 0.24, β= 0.53), miR-
10b-5p levels were significantly elevated from asymptomatic gene carriers to HD 
patients (one-sided p= 0.049, β= 1.15), and on average, miR-10b-5p levels were 
lowest in control subjects (mean=0.00), higher in asymptomatic HD gene carriers 
miRNA
Bonferroni 
corrected one-
sided q-value
-ΔΔCT beta
Direction of 
effect blood 
to brain
miR-10b-5p 0.0068 2.39E+00 + / +
miR-486-5p 0.044 1.44E+00 + / +
miR-132-3p 0.92 -6.22E-01 - / -
miR-363-3p 0.2 -7.93E-02 - / +
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(mean=0.75), and highest in HD patients (mean=2.38). Using a cumulative 
logistic regression to test the ordinal relationship of miRNA levels between 
controls, asymptomatic HD gene carriers and manifest HD patients found a 
significant positive association with miR-10b-5p levels (one-sided p= 2.05e-4, 
cumulative OR =2.27) (see Figure 15), concordant with the direction of the effect 
observed in HD prefrontal cortex.  
 
Figure 15. miR-10b-5p has an ordinal association with HD stage. 
Boxplot of miR-10b-5p levels (-ΔΔCt) for control (in white), asymptomatic HD 
gene carrier (in grey), and manifest HD (in black) subjects. miR-10b-5p had a 
significant, upward, ordinal association to disease stage (one-sided p= 2.05e-4, 
cumulative OR =2.27). Regression analysis revealed differences between 
asymptomatic and HD patients (one-sided p= 0.049, β= 1.15), and differences 
between controls and HD (p= 3.39e-3, Bonferroni-corrected one-sided p= 6.77e-
3, β= 2.39), but not difference between controls and asymptomatic HD patients 
(one-sided p= 0.24, β= 0.53). 	
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Discussion 
The results from this study confirm that two candidate miRNAs, miR-10b-
5p and miR-486-5p, are increased in both brain and blood in HD. Levels of miR-
10b-5p were significant elevated HD patients compared to asymptomatic HD 
gene carriers, and while the miR-10b-5p were not significantly different in 
asymptomatic subjects compared to controls, the ordinal relationship of controls, 
asymptomatic HD and manifest HD suggest premanifest HD miRNAs changes 
may exist.  
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In a previous study, miR-34b was observed significantly increased in both 
an HD cell model and in plasma from premanifest HD patient [31]. However, 
miR-34b alterations were not detected in early or late-stage HD and we did not 
observe a relationship of this miRNA to HD in brain, so it is difficult to interpret 
the utility of this finding [20]. 
While we believe our study is beneficial for clinical biomarker discovery, 
but because of study design limitations, it should be interpreted as a proof-of-
concept experiment. We believe increasing our sample size will provide the 
statistical power for detection of asymptomatic HD gene carriers and controls 
miR-10b-5p differences. More importantly, our study requires an independent 
validation. Research of the DNA damage marker, 8-OHdG, in blood, and its 
relationship to HD progression [13, 32] highlights the importance of biomarker 
validation, as recent studies have yet to reproduce these results [32]. 
Commonly, the inherit variation of data from human samples, coupled with 
the lack of standardization in biological procedures, results in failed cross-
validation. To minimize technical inconsistencies due to the vanishingly small 
RNA quantity in plasma [28], RNA can be directly measured using with RNA 
extraction-free protocols. Firefly Bioworks, which allows for the multiplex analysis 
of up to 68 miRNAs, as well as recent advancements in extraction-free, low input, 
library preparation protocols for miRNA-sequencing, may aid in the orthogonal 
validation of potential miRNA biomarkers. Moreover, these assays allow for 
larger input normalization panels (as opposed to miR-451a/SNORD44), as well 
		 118	
as the measurement of miRNA alterations that were detected in HD prefrontal 
cortex that could not be assessed in this study [20].  
A longitudinal study of miR-10b-5p is critical for assessing the relationship 
of miRNA levels to disease progression within the same subjects, as evaluated 
by motor and cognitive sections of United Huntington’s Disease Ratings Scale 
(UHDRS). The relationship of miRNA levels to functional ratings may be 
potentially confounded by CAG repeat length, as we observed a relationship of 
CAG repeat length to miR-10b-5p levels in brain. Therefore, to establish accurate 
prediction of progressive based on miRNA levels, statistical correction of the 
CAG length should be applied. 
Blood-based biochemical assays are minimally invasive and relatively 
simple compared to neuroimaging-based diagnostics. Here, we demonstrate the 
strength of this study and overall approach, built from alterations observed in HD 
cortex. The miRNA differences in HD blood may resemble changes observed in 
HD brain, which provides greater feasibility that these alterations are 
representative of the disease process, rather than physiological response to HD-
associated weight loss, which is independent to neurodegeneration and other 
disease features [33].  
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CHAPTER 5: DISTINCT MICRORNA ALTERATIONS OBSERVED IN 
PARKINSON’S DISEASE PREFRONTAL CORTEX 
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Abstract 
Objective. The goal of this study was to examine the microRNA (miRNA) 
profile of Parkinson’s disease (PD) frontal cortex as compared to normal control 
brain, allowing for the identification of PD specific signatures as well as the study 
of disease-related phenotypes, such as onset age or dementia. 
Methods. Small RNA sequence analysis was performed from prefrontal 
cortex for 29 PD samples and 33 control samples. After sample QC, 
normalization and batch correction, linear regression was used to identify 
miRNAs altered in PD, and a PD classifier was developed using weighted voting 
class prediction. The relationship of miRNA levels to onset age and PD with 
dementia (PDD) was also characterized in case-only analyses.  
Results. 125 miRNAs were differentially expressed in PD at a genome-
wide level of significance (FDR q<0.05). A set of 29 miRNAs classified PD from 
non-diseased brain (93.9% specificity, 96.6% sensitivity). The majority of 
differentially expressed miRNAs (105/125) showed an ordinal relationship from 
control, to PD without dementia (PDN), to PDD. Among PD brains, 36 miRNAs 
classified PDD from PDN (sensitivity =81.2%, specificity =88.9%). Among 
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differential expressed miRNAs, miR-10b-5p had a positive association with onset 
age (q=4.7e-2). 
Conclusions. Based on cortical miRNA levels, PD brains were accurately 
classified from non-diseased brains. Additionally, the PDD miRNA profile 
exhibited a more severe pattern of alteration among those differentially 
expressed in PD. To evaluate the clinical utility of miRNAs as potential clinical 
biomarkers, brain-related miRNA alterations, in particular, miR-10b-5p, must be 
further characterized and tested in peripheral biofluids.  
Introduction 
Parkinson’s disease (PD) is a progressive movement disorder, 
characterized clinically by resting tremor, rigidity, bradykinesia and postural 
instability [1]. Motor symptoms are accompanied by the loss of dopamine-
producing neurons in the substantia nigra pars compacta, and associated with 
widespread deposition of cytoplasmic protein inclusions, largely composed of 
insoluble α-synuclein, throughout the brain [2].  
PD subtypes can be separated based on distinct, clinical phenotypes. 
Approximately one-third of patients experience dementia (PDD), which has 
significant ramifications for quality of life and burden of care [3, 4]. Additionally, 
there is wide variation in the age of motor onset (ranging from age 20 to age 90) 
[5], with young-onset occurring before age 50 and representing 5-10% of PD 
cases [6]. While neuropathological hallmarks contribute to the degeneration of 
the nigrostriatal dopaminergic system, the etiology, clinical heterogeneity and 
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fundamental pathological mechanisms by which preferential neuronal loss occurs 
in PD are largely unknown.  
The microRNA (miRNA) profile of diseased brains may offer insight into 
the molecular and pathological mechanisms that occur in PD. miRNAs are short, 
noncoding RNAs that inhibit translation through sequence-specific binding of the 
3’-untranslated region (3’UTR) of target messenger RNAs (mRNAs). miRNAs 
can transcriptionally regulate a set or multiple sets of genes simultaneously, and 
in the brain, their regulatory effects have profound effects on neuronal 
development, differentiation and maturation [7]. Deregulation of miRNAs has 
been implicated in neurodegenerative diseases [8], and several studies suggest 
miRNAs may impact PD pathogenesis [9, 10].  
In this study, we performed genome-wide miRNA sequencing of 29 PD 
cases and 33 neuropathologically-normal controls from prefrontal cortex. As 
opposed to microarray technologies that can only detect specific sequences that 
have been chosen a priori, high-throughput sequencing provides a relatively 
unbiased quantification of miRNA molecule abundance. We compared miRNA 
levels between PD and controls and based on their miRNA profile, classified PD 
from non-diseased brains. Among the PD brains, we identified miRNAs 
associated with the presence or absence of dementia and age of motor onset, as 
well as identified a set of miRNAs altered in both PD and Huntington’s disease, 
which may be relevant to the pathological processes that occur in the PD brain.  
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Methods 
Sample information and small RNA sequencing. Frozen brain tissue 
from prefrontal cortex Brodmann Area 9 (BA9) for 29 PD samples and 33 control 
samples was obtained from the Banner Sun Health Research Institute, Sun City, 
Arizona [11], Harvard Brain and Tissue Resource Center McLean Hospital 
Belmont MA, and Human Brain and Spinal Fluid Resource Center VA West Los 
Angeles Healthcare Center, Los Angeles, CA. PD samples had no evidence of 
Alzheimer’s disease comorbidity based on neuropathological examination. 
Sample information can be found in Table S1 and summarized in Table 1. The 
medical charts of all 29 PD samples were reviewed to obtain information 
regarding clinical diagnoses of dementia (PDD n=11, no evidence of dementia 
(PDN) =18). 21 subjects had information on the age of onset of motor symptoms. 
All samples were male. Differences in covariates were tested assuming unequal 
variance. No difference in postmortem interval (PMI) (p-value =0.10) or RNA 
integrity number (p-value = 0.08) was observed between PD and controls. PD 
and controls differed in ages at death (PD mean age = 77.6, control mean age = 
68.1; p-value = 3.2e-3). Potential confounding by age at death was assessed in 
subsequent analyses. PDN and PDD samples did not differ in PMI (p-value 
=0.62), RNA integrity number (p-value =0.27), age at onset (p-value =0.24), 
duration (p-value =0.44), or age at death (p-value =0.28).   
Total RNA was isolated using QIAzol Lysis Reagent and purified using 
miRNeasy MinElute Cleanup columns. Samples were prepared using Illumina’s 
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TruSeq Small RNA Sample Prep Kit, according to the manufacturer’s protocol, 
and sequenced on Illumina’s HiSeq 2000 system with 1x51nt single-end reads at 
Tufts University and the Michigan State sequencing core facility.  
Table 9. Summarized sample information. 
Ages at death were significantly different between controls and PD, as indicated 
(** p<0.01 compared to controls). No differences between PDN and PDD were 
observed. 	
	
 
Statistical analysis. Reads were processed and counted as described in 
Hoss et al. 2015 [12]. R version 3.1.0, Bioconductor version 2.1.4, and DESeq2 
version 1.40.0 were used for variance stabilizing transformation (VST) of count 
data. Batch correction was applied using ComBat using sva 3.10 [13] and LIMMA 
version 3.20.8 [14] was used for differential expression analysis of PD cases and 
controls. All PD samples were from a single batch, therefore DESeq2 
normalized, VST counts from PD samples without batch correction were used for 
the PD-only analyses relating miRNA levels to clinical features. Differential 
expression analysis was performed with and without adjustment for age at death.  
After multiple comparisons correction using a false discovery rate [15], FDR-
adjusted q-values<0.05 were reported as significant. 
Type N Motor Onset Disease duration Age at death
Post mortem 
interval
RNA integrity 
number
Control 33 68.1 ± 14.8 15.0 ± 8.7 7.6 ± 0.7
All diagnosed 
PD 29 66.5 ± 9.8 10.5 ± 6.5 77.6 ± 9.0 ** 11.1 ± 9.7 7.3 ± 0.7
PD, Non 
demented 18 64.1 ± 7.2 11.5 ± 6.4 76.1 ± 8.9 11.9 ± 9.2 7.2 ± 0.8
PD with 
dementia 11 69.8 ± 12.2 9.2 ± 6.7 79.9 ± 9.0 9.9 ± 10.9 7.5 ± 0.5
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To further evaluate the differential expression patterns between PD cases 
and controls, unsupervised, Ward hierarchical clustering by Euclidian distance 
was applied using the heatmap2 function in the gplots R package [16].  
Supervised, predictive modeling of case status was performed using the 
GenePatterns WeightedXVoting module using 29 PD-associated miRNAs with 
large effects [17].  
 To determine if miRNAs were associated with PD in the presence or 
absence of dementia, VST counts for PDN and PDD were compared using 
LIMMA, adjusting for age at death, and p-values were FDR-adjusted for the 
number of comparisons. miRNAs nominally associated with PDD were used to 
classify PD patients with and without dementia, as described above, using the 
weighted voting method. To determine beta estimates relative to control samples, 
PDN and PDD were separately compared to controls using LIMMA. In addition, 
cumulative logit models using the “ordinal” package in R [18], were applied to test 
whether an ordinal relationship existed across control, PDN and PDD samples. 
FDR-corrected Chisq likelihood-ratio tests were used to determine significant 
miRNA associations.  
Linear models were used to model the relationship between age of motor 
onset and miRNA levels among the 21 PD samples with onset data. Tests were 
performed genome-wide and exclusively among the set of differentially 
expressed miRNAs. FDR-adjusted q-values<0.05 were reported. Models were 
run with and without adjustment for age at death. 
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Finally, to determine whether overlap in miRNA alterations exist between 
PD and HD brain, results from PD differential expression analysis were 
compared to those of our previously published Huntington’s disease (HD) study 
[12], which contain the same control brains. HD data was accessed from NCBI’s 
Gene Expression Omnibus, series accession number GSE64977 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64977)  
and analyzed using the same bioinformatics approach for differential expression 
analysis as described above (Bioconductor version 2.1.4, DESeq2 version 1.40.0, 
ComBat sva 3.10, LIMMA version 3.20.8).  
Results 
miRNA levels are altered in Parkinson’s disease compared to non-
disease brains. To identify miRNA differences in PD as compared to non-
disease subjects, miRNA sequence analysis was performed in prefrontal cortex 
(Brodmann Area 9) for 33 controls and 29 idiopathic PD samples (see Table 1). 
Results of differential expression analyses, correcting for sequencing batch 
effects and with and without adjustment for age at death are shown in Table S2. 
125 miRNAs were significantly altered in PD after adjusting for age at death 
(FDR q-value<0.05, see Table S2). Unadjusted results were similar, but 
confounding by age of death was observed for some miRNA, so adjusted results 
are reported here. Most miRNA alterations were moderate, with 77% of the 
differentially abundant miRNAs (96/125) within a ±0.5 log fold change (LFC).  
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The levels of 64 miRNAs were down-regulated, whereas the levels of 61 miRNAs 
were up-regulated in PD relative to controls.  
Next, we used classification models to investigate whether the levels of 
PD-related miRNAs in brain could accurately assign disease status. To select the 
most informative miRNAs, we filtered on effect size (LFC>0.5 or LFC< -0.5). After 
filtering, 29 PD-related miRNAs were used in an unsupervised hierarchical 
cluster analysis. Samples clustered based on disease status with the exception 
of five PD which clustered with the controls, (see Figure 16A). To further assess 
whether miRNA levels could differentiate PD and control samples, disease status 
was predicted using a weighted voting classification with leave-one-out cross-
validation. This model is tested by iteratively leaving one sample out, creating a 
training model by assigning a weighted linear combination based on the levels of 
the 29 miRNAs, and testing this model on the left out sample. Here, only three 
errors were observed using 29 miRNAs (two Type I errors, one Type II error), 
with 93.9% specificity, 96.6% sensitivity and an absolute error rate of 4.8% (see 
Figure 16B). Both Type I errors were called with low confidence (9.8-10.1%).  
miRNA alterations in Parkinson’s disease with dementia. To assess 
whether miRNA differences specific to the PDD subtype were distinguishable 
from a generalized PD response, we performed a differential expression analysis 
comparing PDN to PDD using normalized VST count data from 18 PDN and 11 
PDD samples. We observed no genome-wide significant (q<0.05) miRNAs 
associated with dementia in PD, with or without adjustment for age or disease 
		 129	
duration, after multiple correction testing (see Table S3). Even when limiting to 
the 125 differential expressed miRNAs we saw no significant differences 
between PDN and PDD. We however noted stronger directions of effect in PDD 
when separately comparing PDN versus control and PDD versus control, 
suggesting PDD may represent a more severe version of the PD miRNA profile 
spectrum.  
 
Figure 16. miRNA changes related to Parkinson's disease. 
A. Heatmap of 29 miRNAs differentially expressed between PD and control 
prefrontal cortex samples with log fold changes (LFC) greater than 0.5 or less 
than -0.5. Scaled level values are color-coded according to the legend on the 
right. The dendrogram on the left depicts hierarchical clustering based on level. 
The top dendrogram depicts clustering based on the miRNA signal from each 
sample. The top bar indicates disease status (blue: control, yellow: PD, non-
demented (PDN), orange: PD with dementia (PDD)). B. Disease prediction using 
29 miRNAs. Scores less than zero were called as non-diseased whereas scores 
above zero were called as PD. Blue circles =control, yellow boxes =PD, orange 
triangles = PDN. 
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To test whether PDD had increased miRNA alterations in comparison to 
PDN, we created an ordered categorical variable (controls, PDN, and PDD) and 
tested the association of this variable to genome-wide miRNA levels. 105 of the 
125 differentially expressed miRNAs had a significant ordinal association 
(q<0.05) (see Table S4, and Figure 2A), indicating that in the majority of 
differentially expressed miRNAs in PD, PDD samples exhibit larger differences 
than PDN cases as compared to controls for the same miRNAs.  
Figure 17. miRNA profile for Parkinson's disease with dementia. 
A. Line plot for the 125 DE miRNAs in PD. The counts were scaled using Z-
transformation, and the means were calculated for each miRNA for each 
condition (control, PDN, PDD). The line colors correspond to the beta estimates 
from the ordinal regression analysis, where blue=negative ordered relationship 
and red=positive ordered relationship.  B.  PDN/PDD class prediction, using the 
36 nominally significant miRNAs from PDN/PDD differential expression analysis. 
Four errors were observed among the 29 samples studied. 	
 
We further investigated the clinical utility of these miRNA profiles for the 
assessment of dementia using classification analyses (WeightedXVoting) [17]. 
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The 36 nominally significant miRNAs (p<0.05) identified in the PDN/PDD 
comparison from LIMMA were used to classify disease state (See Figure 2B), 
though with more limited accuracy than the PD-control model (absolute error rate 
=13.8%, sensitivity =81.2%, specificity =88.9%). Four miRNA features overlap 
between the control/PD and PDN/PDD models (miR-132-3p, hsa-miR-132-5p, 
hsa-miR-145-5p, hsa-miR-212-5p). 
miR-10b-5p levels are associated with the onset of motor symptoms 
in both Parkinson’s and Huntington’s disease. To understand whether 
deregulated miRNAs were specific to PD, or a general response to the 
neurodegenerative process, we compared miRNA that were significantly altered 
in PD to those significantly altered in Huntington’s disease (HD). 21 miRNAs 
were found differentially expressed in both PD and HD experiments, and of 
these, only two miRNAs had opposite directions of effect between diseases 
(miR-10b-5p, miR-320b).   
Within the PD case sample, we tested the association of age of motor 
onset of PD with miRNA levels. Although we did not observe significance in a 
genome-wide analysis, restricting our study to the 125 significantly differentially 
abundant PD miRNAs revealed miR-10b-5p to have a significant, positive 
association to onset age (beta=0.040, q-value=4.7e-2, model r2=0.49, see 
Figure 3A). Adding death age increased the magnitude of the effect estimate 
(death adjusted age of onset beta=0.049, p-value onset =3.2e-3, p-value death 
=0.40), although did not stand up to multiple comparisons corrections (q-value 
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onset =0.19). While miR-10b-5p is significantly decreased in PD, miR-10b-5p 
was observed in our previous HD cortical miRNA study [19] to be massively 
increased in HD in comparison to controls (see Figure 3B). Intriguingly, PD and 
HD also exhibit opposite effects with regard to onset age, where miR-10b-5p has 
a strong, negative relationship to age of onset in HD (r2=0.64; r2=0.39 after 
accounting for the contribution of HD gene repeat length) and a strong, positive 
effect in PD (see Figure 3C).  
Figure 18. miR-10b-5p levels are associated with motor onset age in both 
Parkinson's and Huntington's disease. 
A. Comparison of miR-10b-5p level in PD and HD. *q<0.05, **q<0.01, 
***q<0.001, p-values adjusted for genome-wide comparisons. B. Scatterplot of 
miR-10b-5p levels to motor onset age in Parkinson’s disease (PD). In PD, miR-
10b-5p levels exhibit a positive association to onset. C.  Scatterplot of miR-10b-
5p levels to motor onset age in Huntington’s disease (HD). In HD, miR-10b-5p 
levels exhibit a negative association to onset. 	
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Discussion 
Parkinson’s disease related miRNAs. In this study, we identified 125 
miRNAs altered at genome-wide levels in PD prefrontal cortex using next-
generation sequencing. This is the largest miRNA sequencing analysis 
performed in PD versus control brain samples (29 versus 33 respectively), the 
first to provide a detailed miRNA PD profile, classify brains by miRNA levels and 
to evaluate the relationship of miRNA levels in brain to relevant clinical features.  
Reduced levels of miR-133b [9], miR-34b and miR-34c [20], and elevated 
levels of autophagy-related miRNAs, were previously reported [21], and while 
these miRNAs were detectable in our study, we did not observe significant 
changes in their levels. These discrepancies are likely a consequence of the 
different brain regions that were studied (midbrain versus prefrontal cortex), and 
the assay technologies that were used to profile miRNA levels (reverse 
transcriptase quantitative PCR [9, 21], and microarray [20] versus miRNA-
sequencing).  
Several miRNAs that we report altered in PD brain may interact with PD-
related genes. Monogenic forms of PD include mutations within the α-synuclein 
gene (SNCA), Leucine-rich Repeat Kinase 2 (LRRK2), one of the most common 
causes of familial PD [22] and glucocerebrosidase (GBA). While we did not 
observe alterations of SNCA-targeting miRNAs, miR-7 and miR-153 [23, 24], two 
miRNAs shown be regulated by LRRK2 (let-7i-3p/5p and miR-184 [10]) and one 
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miRNA experimentally shown to target LRRK2 expression (miR-1224 [25]), were 
observed to be down-regulated in PD.  
Glucocerebrosidase (GBA) deficiency is associated with PD [26]. We 
observed miR-127-5p, which has been shown to reduce GBA activity [27], to be 
down-regulated in PD brains, and miR-16-5p which has been shown to 
correspond to enhanced GBA protein levels [27], was found to up-regulated in 
brain in our study. It is noteworthy to observe LRRK2-related miRNAs, as none of 
the PD brains in our study had LRRK2 mutations. This may support a role of 
LRRK2 and GBA in PD, independent of that produced by the known mutations in 
these genes. 
Classification based on miRNA abundance. We were able to classify 
PD based on the levels of 29 miRNAs with less than a 5% error rate. Although 
this classification was performed using postmortem brain samples, we believe 
this may be relevant for PD biomarker discovery, particularly if these miRNAs are 
peripherally detectable. We reasonably differentiated PD subtypes (PDN/PDD) 
based on miRNA levels, and we observed a pattern of increased changes in the 
PDD samples relative to the PDN samples in the set of altered miRNAs. We 
observed that the majority of differentially expressed miRNAs had an ordinal 
relationship to controls and PD cases stratified by the presence or absence of 
dementia, suggesting PDD may represent a more severe alteration of the PD 
miRNA profile. 
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PD-related miRNA changes in biofluids. Our study in PD brains 
identified profiles of miRNAs that distinguish PD from controls, which if also 
observed in peripheral biofluids, such as blood or cerebrospinal fluid (CSF), 
could be valuable in the evaluation of PD diagnosis, prognosis, or progression. 
The small size (~22 nucleotides) of miRNA may allow for neuropathologically 
altered miRNA to cross the blood-brain barrier in exosomes [28] and circulate 
stably in peripheral fluids as cell-free molecules [29]. Although there was no 
overlap of miRNAs in brain to changes observed in most PD blood studies [30-
34], we did observe increased levels in one (miR-29a-3p) of three miRNAs 
previously reported as increased in blood of PD patients after Levodopa 
treatment [35]. In Burgos et al. 2014, small RNA sequencing was performed for 
blood serum and CSF from 67 PD and 78 control subjects [36], five miRNAs 
were found significantly altered in PD serum and 17 were significantly altered in 
CSF. Of these 22 miRNAs, five showed consistent overlap with our cortical 
findings, with one from serum (miR-1294) and four from CSF (miR-132-5p, miR-
127-3p, miR-212-3p, miR-1224-5p). Thus, miRNAs detected in CSF may have a 
stronger relationship with brain miRNAs levels than those detected in serum.  
Common miRNA changes in PD and HD. We previously reported 75 
miRNAs altered in HD prefrontal cortex [12], and when comparing miRNAs 
altered in both PD and HD, 21 miRNAs were observed deregulated in both 
diseases. Among the miRNAs with concordant changes in PD and HD, a several 
miRNAs correlated with various HD clinical features, such as the extent of striatal 
		 136	
degeneration and duration of the disease [12]. These miRNAs may represent a 
generalized, neurodegenerative response in the prefrontal cortex, which relate to 
severity and/or progression across these diseases. However, it is important to 
recognize that the results from the PD and HD studies are not independent, as 
they were both analyzed using the same 33 control brains.  
Of the two miRNAs with discordance between PD and HD, miR-10b-5p 
emerged due its relationship to onset in both diseases. miR-10b-5p is markedly 
increased in HD in comparison to controls, and has a negative association to age 
of onset for HD, with higher levels of miR-10b-5p corresponding early onset age. 
In contrast, miR-10b-5p is significantly decreased in PD, and has a positive 
association to onset age, where higher miRNA levels correspond to later onset 
ages. In a separate Alzheimer’s disease (AD) study, examining miRNA levels in 
prefrontal cortex, miR-10b-5p levels were significantly reduced in AD [37]. 
However, at the very earliest stages of AD, miR-10b-5p levels clustered with up-
regulated miRNAs whereas at early to middle stages, miR-10b-5p levels 
appeared to decline [37]. The relationship of miR-10b-5p to these three age-
related, neurodegenerative diseases suggests a complicated pattern of miR-10b-
5p alteration in response to the neurodegenerative or pathologic protein 
aggregation processes. 
Conclusion 
This study provides evidence that miRNA levels are altered in PD 
prefrontal cortex. These changes are sufficiently consistent that diseased brains 
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can be discriminated with high confidence from non-diseased brains based on 
the level of 29 miRNAs. PDD may represent a more severe profile of PD related 
miRNAs than PDN. 21 miRNAs changes were similar between PD and HD, with 
the exception of miR-10b-5p, which had opposite direction of effects to disease 
association and to motor onset age in the two diseases. Further characterization 
of miR-10b-5p in the neurodegenerative disease context is warranted to better 
understand if it has clinical potential as a biomarker for disease progress or to 
identify potential therapeutic targets. 
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Conclusion 
Summary of Aims 
miRNAs are altered in HD brain, several of which relate to clinical 
phenotypes, such as onset age and striatal degeneration. This effect is CAG-
independent, and likely independent of both death age and cortical involvement.  
In particular, miR-10b-5p levels have the strongest associations to these 
features, where increased levels in HD brain predict earlier onset age and more 
striatal involvement. Levels of miR-10b-5p are increased in asymptomatic and 
grade 2 brains, indicating the levels of this miRNA are increased pre-clinically or 
within the early stages of the disease process.  
In plasma, we found two miRNAs (miR-10b-5p and miR-486-5p) that were 
significantly altered. These same miRNAs exhibited nominal association (p<0.05) 
to CAG-adjusted onset (miR-10b-5p and miR-486-5p) and to CAG-adjusted 
striatal involvement (miR-10b-5p) in the HD cortical study. Levels of both 
miRNAs were elevated in both HD plasma and brain. miR-10b-5p levels were 
observed to be slightly elevated in asymptomatic HD and significantly increased 
in manifest HD compared to healthy controls, which suggests miR-10b-5p 
changes occur in HD, and may increase in plasma during the transition from 
premotor to manifest HD. 
We identified significant differences in miRNA levels in PD brain and 
based on a set of deregulated miRNAs, we were able to classify PD and non-
diseased brains with high accuracy. The miRNA profile of PDD suggests PDD 
		 142	
has a more extreme molecular phenotype than PDN. A comparison with our 
previous Huntington’s disease (HD) study, which used the same set of control 
brains, revealed a set of miRNAs altered in both PD and HD. When testing for 
the association of differentially expressed miRNAs to age at onset, miR-10b-5p 
had a significant, positive relationship. In contrast to HD, miR-10b-5p was slightly 
decreased in PD and increased levels of miR-10b-5p were observed in 
individuals with late-onset.  
Overall conclusion 
 
These studies provide a detailed miRNA profile for HD and PD brain, 
identify miRNAs associated with disease pathology and suggest miRNA changes 
observed in brain can be detected in blood. Together, these findings support the 
potential of miRNA biomarkers for the diagnosis and assessment of progression 
for neurodegenerative diseases. 
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APPENDIX 
Table S2.1. miRNA RT-qPCR validation study results.  
Table S2.2. Sample information for eight Huntington's disease brains used 
for RT-qPCR replication study.  
Table S2.3. Sample information for eight control brains used for RT-qPCR 
replication study.  
Table S2.4. miRNA RT-qPCR replication study results.  
Table S2.5. Sample information for fourteen Parkinson's disease brains 
used for RT-qPCR replication study.  
Table S2.6. Read statistics for miRNA-sequence analysis.  
Table S2.7. Mean and standard deviation inner-distance estimates for 
TopHat2 alignment.  
Table S2.8. Read statistics for mRNA-sequence analysis. 
Table S3.1. Sample information for 36 control brains used for miRNA-
sequencing. 
Table S3.2. Sample information for 28 Huntington’s disease brains used for 
miRNA-sequencing. 
Table S3.3. Read statistics for miRNA-sequence analysis. 
Table S3.4. Correlation of differentially expressed miRNA precursor pairs. 
Table S3.5. Summary statistics for Firefly BioWorks assay. 
Table S3.6. Linear regression analysis modeled the relationship of miRNA 
expression and Vonsattel grade. 
 
Table S5.1. Detailed sample information.  
Missing information is designated as “NA”. 
 
Table S5.2. Results from miRNA differential expression analysis in 
Parkinson’s disease.
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